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Abstract 
Polo like kinase 1 (PLK1) has many functions in the orchestration of cell 
division. It is an oncogene and its overexpression is associated with poor 
prognosis. PLK1 is a cell cycle-dependent protein; its levels are low in the early 
phases of the cell cycle and increase as cells go through the cycle, peaking in 
G2/M. In this thesis, our focus has been on two critical areas in PLK1 research. 
1. Tumour suppressor p53 mediates transcriptional repression of PLK1. There
have been several mechanisms suggested for this repression both by direct and 
indirect p53 involvement. In light of the recently proposed mechanism 
suggesting that p53-p21-DREAM-CDE/CHR is responsible for p53 mediated 
repression of G2/M proteins (including PLK1), we reassessed the event(s) by 
which p53 downregulates PLK1. While investigating the effect of different p53 
stabilising agents on PLK1 levels, different agents were found to give rise to 
different cell cycle profiles. This could account for differences in the extent of 
PLK1 downregulation in response to different agents: i.e. that the levels of PLK1 
after treatment reflect the phase in which the cycle is arrested. Further 
investigation showed that p53 mediated repression of PLK1 is partly p21 
dependent, consistent with repression occurring (partly) through DREAM. Also, 
we found that different cells use different or overlapping mechanisms for this 
repression. Thus While in HCT116 cells, mutation of CDE/CHR elements 
(through which DREAM acts) abolished the PLK1 repression, U2OS cells were 
only partly dependent on CDE/CHR elements for this repression. Additionally, 
Serine 15 phosphorylation was found to be partly required for the repression 
and only wild type p53 (but not mutated forms of p53 that lack transactivation 
xx 
 
capacity) could repress PLK1 expression. These data are consistent with the 
idea that p53 repression is indirect, but do not rule out other mechanisms.  
2. PLK1 has been extensively studied as a target for cancer therapeutics. PLK1 
inhibition causes arrest in prometaphase and activation of the DNA damage 
response. Part of this thesis aimed at investigating the DNA damage response 
(DDR) induced in mitosis by PLK1 inhibitor and the consequences of such 
inhibition. Also, the results were compared with the results obtained/reported in 
response to microtubule poison, nocodazole. Our investigations showed some 
differences in the mitotic arrest-induced DDR observed by PLK1 inhibition and 
microtubule poisons. PLK1 inhibition resulted in both telomeric and non-
telomeric γ-H2AX foci which were not caspase/CAD dependent, whereas 
nocodazole treatment resulted in caspase dependent DNA damage which was 
mostly on telomeres. DNA damage sensing protein kinases involved in DDR by 
PLK1 inhibition were found to be ATR and DNA-PK, whereas for nocodazole 
DNA-PK was the main kinase involved. Also, in clonogenic survival assays, 
more surviving colonies were observed in response to PLK1 inhibitor as 
compared with nocodazole treatment. Interestingly, PLK1 inhibition resulted in 
recruitment of the 53BP1 (one of the components of the DNA repair pathway) in 
mitosis which may not be beneficial and suggests further investigations on 








1.1 Polo Like Kinases (PLKs) 
Polo was the first identified PLK family member which was discovered in 1988 
from Drosophila’s genetic screens for mutants that could not undergo normal 
mitosis and meiosis (Sunkel & Glover, 1988). It is a serine/threonine kinase and 
is highly conserved between species from yeast to humans; each species 
having between one to several orthologues. However, in plants it has been 
reported that there are no PLKs (Karpov et al., 2010). In Humans five 
homologues of polo have been identified to date (PLK1, PLK2, PLK3, PLK4 and 
PLK5).  
PLKs are important regulators of the cell cycle progression and maintain DNA 
integrity. They orchestrate cell division through cooperation with Cyclin-
dependent kinases (CDKs) (Strebhardt and Ullrich, 2006). The structures of all 
PLKs are similar to one another with two main features in their structure: (a) the 
amino terminal (N-terminal) kinase domain that can regulate the cellular 
functions of specific proteins by transferring phosphate groups from ATP to their 
serine/threonine amino acids, (b) a regulatory polo box domain which contains 
two (three in case of PLK4) signature motifs known as polo boxes at the 
carboxyl domain (C-terminal) which regulates the cellular localization of PLK1 
and its substrate binding (Barr et al. 2004; Zitouni et al. 2014). The structure of 
PLK family proteins are depicted in Figure 1-1.  
PLK1 is the most conserved member of the family and its functions in cell cycle 
progression have been better studied and understood. The Focus of this Thesis 
is on PLK1, but before going through PLK1, a brief introduction on other 








Figure 1-1. Schematic diagram of human PLK family structures.  
Members of PLK family are depicted in the schematic. PLK1-4 all contain a protein kinase domain 
(green) in their N-termini. PLK1 activity is enhanced by phosphorylation at threonine 210 (T210) in the 
activating T loop, in the kinase domain. The residues equivalent to threonine 210 are conserved in PLK2, 
PLK3 and PLK4, as depicted. PLK5 contains the final fragment of the kinase domain only, due to an in-
frame stop codon in exon 6 which is followed by a conserved ATG in the boundary of exons 6 and 7. 
PLK1, 2, 3 and 5, contain two polo boxes (PBD1 and PBD2, blue). PLK4 contain a cryptic polo box 





PLK5 is the most recently identified PLK family and therefore not much 
research has been done on it (Andrysik et al., 2010). PLK5 can be found in 
vertebrates only. Interestingly, human PLK5 lacks the catalytic kinase domain in 
the N terminus because of a stop codon in exon 6 which is followed by a 
conserved ATG in the boundary of exons 6 and 7.  This results in expression of 
a short protein with final fragment of the kinase domain, the linker region and 
polo box 1 and 2. PLK5 has been reported to be expressed in the eye, brain 
and ovary of mice (de Carcer et al., 2011). PLK5 expression is seen in nucleoli 
and can be induced by DNA damaging agents. The stress response of PLK5 
has been reported to be independent of p53 (in contrast to PLK2 and PLK3). 
PLK5 downregulation has been reported in many brain tumours (de Carcer et 
al., 2011) and its overexpression results in G1  arrest, DNA synthesis reduction 
and apoptosis (Andrysik et al., 2010). This suggests its tumour suppressive 
activity. 
1.1.2 PLK4 
PLK4 (SNK/PLK-akin kinase) seems to be the most structurally divergent Polo 
family member. In the structure of PLK4, there is a cryptic polo box domain 
consisting of two tandem polo box domains (PBD1 and PBD2) and a third polo 
box (PB3) (Slevin et al., 2012). PLK4 is a cell cycle dependent protein and its 
expression is low in G1 and gradually increases in S phase through M phase 
(peaks in M) (Fode et al., 1994). PLK4 is highly expressed in high proliferative 
tissues and has been shown to be critical in mouse embryonic development 
(Swallow et al., 2005). The best characterised function of PLK4 is in centriole 
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duplication during S phase (Habedanck et al., 2005). PLK4 has been shown to 
be downregulated by p53, however despite the fact that there are three p53 
binding sites in the promoter region of PLK4, p53 does not bind to these sites, 
suggesting an indirect repression mechanism (Li et al., 2005). 
1.1.3 PLK3 
PLK3 (Proliferation-related kinase, PRK) was first characterised as a fibroblast 
growth factor 1 (FGF1)-induced immediate early gene (Donohue et al., 1995). It 
is believed to be a stress induced tumour suppressor; in response to DNA 
damage PLK3 activity increases rapidly in an ATM dependent manner (Helmke, 
Becker and Strebhardt, 2016).  
PLK3 is a p53 target gene and upon irradiation its transcription is activated by 
p53 through a p53 responsive element (p53RE) in PLK3 promoter (Jen and 
Cheung, 2005). PLK3 interacts with p53 and phosphorylates it on serine 20 
leading to p53 stabilisation and checkpoint activation. This finding suggests that 
PLK3 is a tumour suppressor and functions in regulating cell proliferation (Xie et 
al., 2001).   
The expression of PLK3 and its cell cycle dependency remain unclear as 
different laboratories reported differently (Bahassi et al., 2002; Zimmerman and 
Erikson, 2007; Chase et al., 1998; Ouyang et al., 1997). PLK3 has been 
reported to be downregulated in some cancers including lung, head and neck, 




Like PLK5, PLK2 is found in vertebrates only. PLK2 (Serum inducible kinase, 
Snk) is believed to be a tumour suppressor as it is downregulated in some 
cancers and its ectopic expression results in apoptosis (Syed et al., 2006). 
PLK2 has been reported as a transcriptional target of p53, with three p53 
binding sites in the promoter region of its gene; two sites for p53 mediated 
transcriptional activation and one for repression (Burns et al., 2003). PLK2 has 
also been reported to be induced, in a p53 dependent manner, following 
irradiation and activation of the G2/M checkpoint, suggesting that it is a stress 
response gene (Shimizu-Yoshida et al., 2001; Burns et al., 2003). PLK2 has 
been suggested to have a role in centriole duplication which is dependent on 
PLK4 (Cizmecioglu et al., 2008). 
1.2 PLK1 
PLK1 is the first discovered and best characterised of PLK family. It was first 
identified in 1994 and the founders/authors reported it being maximally 
expressed in tissues with a high mitotic index suggesting its function in cell 
proliferation (Golsteyn et al., 1994). PLK1 consists of 603 amino acids and its 
molecular mass is approximately 68 kDa. PLK1 expression, activity and 
localisation need to be tightly regulated throughout the cell cycle to ensure 
chromosome stability/integrity (Liu, Sun and Wang, 2017). 
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1.2.1 PLK1 structure and localization 
As mentioned before, all members of the PLK family, including PLK1, contain 2 
functional domains; N terminal kinase domain and C terminal polo box domain 
(comprises 2 polo boxes which function as a single unit). Both of these domains 
are required for PLK1 activity. Phosphorylation of threonine 210 (T210) in the T 
loop of PLK1 by Aurora A enhances the catalytic activity of PLK1. This 
phosphorylation induces a stable conformational change which enables PLK1 
interaction with other molecules (Lowery, Lim and Yaffe, 2005). Activated PLK1 
can then localise to the specific sites (phospho-serine/threonine containing 
peptides) through its PBD which is a phosphopeptide (phospho serine or 
phospho threonine) binding domain (Elia, Cantley and Yaffe, 2003). 
Interestingly deletion of PBD of PLK1 resulted in substantial increase in its 
catalytic activity suggesting a role for PBD in negatively regulating PLK1 activity 
(Mundt et al., 1997).  
Binding of PLK1 PBD to proteins that have already been phosphorylated and 
marked as a docking site for the PBD, shows that priming phosphorylation of 
the substrate is crucial for the PLK1 localisation and functions (Elia, Cantley and 
Yaffe, 2003). The priming phosphorylation/generation of the phosphoepitope 
happens either by self priming (by PLK1) or by a pro-directed kinase (such as 
CDK1) (Lee et al., 2008). After localisation of PLK1 by PBD, PLK1 kinase 
domain can perform its functions by phosphorylating its substrates. 
PLK1 localization is highly dynamic and differs in each step of the cell cycle. 
During interphase and prophase PLK1 is localised at centrosomes but then in 
prometaphase and metaphase it moves to the kinetochores and spindle poles 
to regulate assembly of the kinetochores and contribute to the spindle assembly 
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checkpoint (Degenhardt and Lampkin, 2010). It then translocate to the central 
spindles and midzone/midbody in anaphase and telophase (Zitouni et al., 
2014).  
1.2.2 PLK1 functions 
PLK1 is a major kinase in mitosis and functions almost in every step during 
mitosis. It has roles in mitotic entry, centrosome maturation, bipolar spindle 
formation, chromosome segregation and mitotic exit/cytokinesis. Below is a 



















Figure 1-2. PLK1 functions throughout the cell cycle.   
PLK1 has many roles during the cell cycle. The most well studied functions of PLK1 are in mitosis. PLK1 
has been shown to be involved in various aspects of mitotic progression such as mitotic entry, 
centrosome maturation and separation, spindle assembly, APC/C regulation and cytokinesis. Non-







The first main function of PLK1 in mitosis is to promote mitotic entry. The key 
to entry into mitosis is the activation of CDK1-Cyclin B. CDK1 is phosphorylated 
and inhibited by WEE1 and MYT1 protein kinases and de-phosphorylated and 
activated by CDC25C phosphatase. In order to promote mitotic entry, PLK1 
activates CDK1-Cyclin B1 by inhibiting WEE1 and MYT1 and activating 
CDC25C (Toyoshima-Morimoto et al., 2001; Van Vugt, Brás and Medema, 
2004; Nakojima et al., 2003). There’s also evidence that PLK1 can promote 
mitotic entry by direct phosphorylation of Cyclin B1 at centrosomes (Toyoshima-
Morimoto et al., 2001) 
In response to DNA damage, PLK1 is inactivated through phosphorylation by 
ATM and cell cycle halts (Van Vugt and Medema, 2005). In order to resume cell 
cycle progression (this is called recovery), activity of PLK1 is required. 
Synergistic cooperation of Aurora kinase A and its co-factor Bora, results in 
direct phosphorylation of PLK1 at threonine 210 by Aurora A (occurs several 
hours prior to mitotic entry). This enhances the catalytic activity of PLK1 which 
then results in CDK1 activation and mitotic entry (Macůrek et al., 2008; Seki et 
al., 2008). Even though PLK1 functions in activation of CDK1-Cyclin B1 
complex, it appears that its activity is not essential for entry into mitosis as using 
an inhibitor of PLK1 does not block mitotic entry but instead results in mitotic 
arrest (Steegmaier et al., 2007). 
The next role of PLK1 is centrosome maturation. Centrosomes are the 
microtubule-organizing centre (MTOC) in animal cells. They consist of two 
centrioles and the surrounding pericentriolar material (dense mass of proteins 
such as γ-tubulin, pericentrin and ninein, which are involved in microtubule 
nucleation and anchoring) (Schatten, 2008). Centrosomes duplicate during S 
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phase and their maturation occurs in preparation for mitosis. In this process 
accumulation of γ-tubulin ring complexes and recruitment of other components 
leads to morphological and biochemical changes in pericentriolar material 
(Khodjakov and Rieder, 1999). These changes enhance the microtubule 
nucleation potential.  
PLK1, has been suggested to phosphorylate pericentrin, an initiating step in 
centrosome maturation which results in recruitment of γ-tubulin and other 
pericentriolar material proteins (Sunkel and Glover, 1988; Lane and Nigg, 1996; 
Nigg, Blangy and Lane, 1996; Lee and Rhee, 2011) . PLK1 also phosphorylates 
a centrosomal protein called Nlp (ninein-like protein) which is involved in 
microtubule anchoring and nucleation. During interphase, Nlp interacts with γ-
tubulin ring complexes to assist in microtubule organisation. During mitosis, 
however, phosphorylation of Nlp leads to displacement of Nlp from 
centrosomes. This replacement has been proposed to be a prerequisite for the 
recruitment of other proteins (still unidentified), which then results in increased 
microtubule nucleation potential (Casenghi et al., 2003).  
PLK1 also has roles in centrosome separation which is required for the 
formation of bipolar spindles. PLK1 targets Eg5, a kinesin like motor protein 
also known as KIF11, which hydrolyses ATP to convert chemical energy into 
mechanical work (Zima, 1998). PLK1 in conjunction with CDK1 phosphorylates 
NEK9 in prophase. Activated NEK9 then phosphorylates and activates NEK6/7, 
leading to Eg5 phosphorylation and its localisation/recruitment to the 
centrosomes (Bertran et al., 2011).  
PLK1 depletion has been shown to reduce the number of attached microtubules 
to the kinetochores. Kinetochores are protein structures at the centromere of 
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chromatids at which spindle microtubules attach. As mentioned before, PLK1 
localises to the kinetochores in prometaphase, which further indicates that it 
may function at these cellular elements to perform its role in stabilising  
microtubule-kinetochore attachments (Sumara et al., 2004). PLK1 
recruitment to the kinetochores has been reported to be dependent on a protein 
at the centromere called PBIP (polo box interacting protein 1) (Kang et al., 
2006). PLK1 uses a self-priming mechanism and phosphorylates PBIP1 to 
create a binding site for PBD and dock itself to centromere (Kang et al., 2006). 
However, in early mitosis, PLK1 causes delocalization and degradation of 
BPIP1 from kinetochores (Kang et al., 2006), whereas PLK1 continues to be 
localised at kinetochores until telophase. This shows that there should be other 
proteins contributing to PLK1 localisation at kinetochores. BubR1 is one of the 
PLK1 substrates whose phosphorylation by PLK1 has been suggested to be 
important for stable microtubule-kinetochore attachments. Elowe et Al. showed 
that BuBR1 phosphorylation by PLK1 at unattached kinetochores which are not 
under tension is higher than attached kinetochores. This phosphorylation 
continues until metaphase when the tension has established between sister 
chromatids (Elowe et al., 2007). 
As PLK1 levels are particularly higher in the kinetochores of unattached 
chromosomes (which are not under tension) (Ahonen et al., 2005) and because 
PLK1 phosphorylates substrates required for spindle assembly checkpoint 
(SAC) activation such as BubR1, Bub1 and PICH (Qi, 2006, Suijkerbuijk et al., 
2012; Baumann et al., 2007), it has been suggested that PLK1 might have roles 
in the SAC activation. However, PLK1 inhibition causes prolonged arrest in 
prometaphase as a result of SAC activation (as evidenced by bright and intense 
staining of SAC proteins, Bub1, BubR1 and Mad1) (Lénárt et al., 2007). So, the 
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role of PLK1 in unattached kinetochores is perhaps in regard to promoting 
proper microtubule-kinetochore attachment and not related to regulation of 
SAC. 
Localisation of PLK1 to the central spindles and midbody in late anaphase and 
telophase respectively suggested its role during late stages of the cell cycle. 
PLK1 initiates mitotic exit by inhibitory phosphorylation of Emi1 (early mitotic 
inhibitor 1) which leads to activation of E3 ubiquitin ligase APC/C (anaphase 
promoting complex/cyclosome). This results in cyclin B degradation by 26S 
proteasome and hence inactivation of CDK1 (Moshe et al., 2004).  
PLK1 also recruits RhoGEF Ect2 to the central spindles (during anaphase). This 
protein has a fundamental role in signalling from the midzone to the cortex 
which is a requirement for cytokinesis induction. This promotes the activation of 
RhoA GTPase which causes generation of cleavage furrow by assembling and 
regressing the contractile ring and initiating cytokinesis (Petronczki et al., 
2007). 
In addition to its critical role in mitosis, PLK1 has been reported recently to have 
functions in DNA replication during S phase. An RNAi approach used by Yim 
and Erikson  showed that PLK1 is required for DNA replication during cell cycle 
progression as depletion of PLK1 caused disruption of the pre-replicative 
complex formation at G1/S transition and reduction in DNA synthesis during S 
phase (Yim and Erikson, 2009). Also, PLK1 recruitment to the centrosomes by 
centrosomal protein FOR20 (FOP-related protein of 20 kDa) has been shown to 
be essential in DNA replication and S phase progression (Shen et al., 2013). In 
another study, Orc2 (origin recognition complex 2), one of the subunits of pre-
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replicative complex, has been reported as a target of PLK1 under stressed 
conditions. PLK1 phosphorylates Orc2 at serine 188. This phosphorylation is 
enhanced when DNA replication is under challenge. Cells that express an Orc2 
mutant (S188A), failed to maintain the functional pre-replicative complex in 
response to  DNA replication stress (Song et al., 2011). 
1.2.3 PLK1 and cancer 
Consistent with its functions in cell division and proliferation, it is not surprising 
that PLK1 has been linked to both development and progression of cancers. 
PLK1 overexpression has been reported in many cancer types including non-
small cell lung cancer (Wolf et al., 1997), breast cancer (Wolff et al., 2000), 
(Weichert et al., 2005; A Ahr et al., 2002), ovarian cancer (W Weichert et al., 
2004a), colorectal cancer (Takahashi et al., 2003), glioblastoma (Dietzmann et 
al., 2001), pancreatic cancer (Gray  Jr. et al., 2004), gastric carcinoma 
(Tokumitsu et al., 1999), head and neck squamous cell carcinoma (Knecht et 
al., 1999) , melanoma (Strebhardt et al., 2000; Kneisel et al., 2002), prostate 
cancer (Wilko Weichert et al., 2004) and non-Hodgkin lymphoma (Mito et al., 
2005). PLK1 overexpression is a marker of poor prognosis and has been linked 
to higher tumour grades and increased risk of metastasis (Wolf et al., 1997; 
Wilko Weichert et al., 2004; W Weichert et al., 2004; Kneisel et al., 2002; Ahr et 
al., 2002; Zhang, Zhang and Kong, 2013). A study conducted by King and 
colleagues showed an association between PLK1 overexpression and p53 
mutation. Also, patients who had both PLK1 overexpression and p53 mutation 
showed worse survival as compared to patients having only PLK1 
overexpression or p53 mutation (King et al., 2012). 
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As PLK1 is rarely mutated, it had been suggested that overexpression of PLK1 
in cancer cells might be a consequence of cancer (and increased proliferation) 
and not the cause of it. But ectopic/constitutive expression of PLK1 in a normal 
mouse embryonic fibroblast line (NIH3T3) resulted in the malignant 
transformation of the cells and allowed them to grow in soft agar and caused 
tumours in nude mice, indicating its oncogenic potential (Smith et al., 1997). In 
line with that, there has been evidence that rate of proliferation and cell cycle 
progression of cancer cells (but not normal cells) is highly suppressed by PLK1 
depletion. This indicates that cancer cells are highly addicted to PLK1 and 
hence validating PLK1 as a potential therapeutic target (Liu, Lei and Erikson, 
2006).  
1.2.4 PLK1 small molecule inhibitors 
PLK1 has been extensively studied as a target for cancer therapy as it is 
required for the survival and proliferation of the cells and is overexpressed in 
many cancer types (Lénárt et al. 2007, Rudolph et al. 2009). Overexpression of 
PLK1 has been reported to cause multi-nucleation (Mundt et al., 1997). 
Expression of hyperactive PLK1 in cells that undergo DNA damage-induced G2 
arrest causes recovery from G2 arrest (Van Vugt, Brás and Medema, 2004). 
Constitutive expression of PLK1 caused malignant transformation of 
mammalian cells (Smith et al., 1997). Also, PLK1 phosphorylates tumour 
suppressor p53 to inhibit its transactivation activity and pro-apoptotic function 
(Ando et al., 2004). All this, evidence, indicates that PLK1 is a strong target for 
therapeutic intervention for cancer. 
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Several PLK1 small molecule inhibitors have been manufactured and are in pre-
clinical or clinical development. They are capable of inducing mitotic arrest and 
cause apoptosis in several cancers (Lénárt et al. 2007; Rudolph et al. 2009). As 
with any other anti-mitotic drug, PLK1 inhibitors maintain the spindle assembly 
checkpoint activated and prevent the cell cycle progression. PLK1 inhibition has 
shown promising results in different haematological and solid tumours 
(Strebhardt, 2010; Schöffski, 2009).  
PLK1 inhibitors either target the kinase domain of PLK1 (ATP competitive 
inhibitors) or the PBD (non-ATP competitive/ substrate specific inhibitors). As 
the ATP binding pocket is a classic target for the design of kinase inhibitors, the 
first PLK1 inhibitors were those targeting the kinase domain. These inhibitors 
reduce PLK1 expression by interfering with its catalytic activity. BI2536 is an 
example of this class of inhibitors which we have used in this thesis (chapter 4). 
One drawback of such ATP competitive inhibitors is that the high conservation 
of ATP binding sites in different kinases provides challenges in identifying 
inhibitors with the appropriate specificity. Also, developing resistance to 
inhibitors that target the ATP binding site is not uncommon as there are 
chances of mutations in the kinase domain (Daub, Specht and Ullrich, 2004). 
So, in the light of making inhibitors that do not compete with the ATP and 
instead they compete for the PLK1 substrates, inhibitors that target the PBD 
were identified. PBD is specific to PLKs and hence a potential target to develop 
selective inhibitors. However, some of the PLK1 substrates do not require 
interaction with PBD to be recognised by PLK1 kinase domain for 
phosphorylation. This brings limitations into the development of inhibitors of 
PLK1 which target PBD (Park et al., 2010).  
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BI2536: It is a potent, ATP competitive inhibitor of PLK1 with an IC50 value of 
0.83 nM. It is well tolerated and acts with high specificity and selectivity (more 
than 1000 fold more selectivity for PLK1 compare to a large panel of other 
kinases) (Schöffski, 2009). However, it has effects on the activity of other PLKs 
such as PLK2 and PLK3 (which are potential tumour suppressors) with relative 
IC50s of 3.5 nM and 9 nM respectively. Nevertheless, since other PLK 
members are believed to have their roles in G1 and S phases, BI2536 is 
considered to be a specific inhibitor of PLK1 during mitotic phase (Lénárt et al. 
2007). BI2536 leads to arrest in prometaphase, aberrant mitotic spindles and 
cell death in a large panel of cancer cell lines (Lénárt et al. 2007, Steegmaier et 
al. 2007). Moreover in vivo studies demonstrated a high efficacy at well-
tolerated doses causing regression of human tumour xenografts in nude mice 
(Steegmaier et al., 2007). It is now used in clinical studies of patients with 
advanced or metastatic cancers and has been reported to be well-tolerated with 
neutropenia as the main side effect (Strebhardt, 2010).  
1.2.5 Cell cycle Regulation of PLK1 levels and enzymatic activity 
PLK1 levels are tightly regulated throughout the cell cycle at mRNA and protein 
levels. Golsteyn and colleagues showed that PLK1 protein levels and 
distribution changes as cells go through the cell cycle and peak in G2/M. They 
also showed that tissues with high mitotic index show more PLK1 expression, 
consistent with its role in cell proliferation (Golsteyn et al., 1994).  
Various transcriptional repressors and activators are involved in early and late 
phases of the cell cycle respectively for PLK1 transcriptional regulation. There 
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are elements/sequences in the promoters (close to transcription start site) of 
genes with high expression in late stages of the cell cycle such as PLK1 and 
CDC25C. These elements are called CDE/CHR (cell cycle dependent 
element/cell cycle gene homology region) and are believed to be responsible for 
cell cycle dependency of these genes by negatively regulating them in early 
stages of the cell cycle. Deletion mutation in this region was shown to cause 
loss of cell cycle specific transcriptional regulation of PLK1 as evidenced by 
increased PLK1 level in G1 (Uchiumi, Longo and Ferris, 1997).  
The mechanism by which PLK1 and other CDE/CHR contained promoters are 
regulated is through the action of DREAM complex (DP, RB-like, E2F and 
MuvB). It is composed of MuvB core complex (multi vulval class B; LIN9, LIN37, 
LIN52, LIN54 and RBBP4), E2F4-5, DP1 (dimerization partner 1) and pocket 
proteins p130 or p107 (related to the retinoblastoma tumour suppressor pRB) 
(Litovchick et al., 2007). The repression mechanism is based on the 
hypophosphorylation state of RB-like pocket proteins p130/p107 in early phase 
of the cell cycle. In this state, p130/107 join other proteins and form the DREAM 
complex. Binding of DREAM to CDE/CHR elements represses the transcription 
(Mannefeld, Klassen and Gaubatz, 2009; Guiley et al., 2015; Litovchick et al., 
2007) (Figure 1-3).  
As the cells progress through the cell cycle, activated cyclin/CDK progressively 
phosphorylates p130/p107 leading to their deactivation and disassembly of 
DREAM complex (Guiley et al., 2015). Additionally and importantly, the 
transcriptional repressors p130/107 and E2F are substituted with activators B-
MYB and later FOXM1. MuvB association with B-MyB or FOXM1 switches the 
repressive DREAM complex to B-MYB-MuvB complex (MMB), FOXM1-MMB 
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complex or FOXM1-MuvB complex (Sadasivam, Duan and DeCaprio, 2012; 
Sadasivam and DeCaprio, 2013). This is a switch where the complex become 
an activator. This switch in protein binding to CDE/CHR is responsible for the 















Figure 1-3. Schematic representation of PLK1 transcriptional regulation during the cell cycle.  
The repression of PLK1 in G0/G1, is based on the hypo phosphorylation of RB-like pocket proteins 
p130/p107. Hypophosphorylation state of p130/107 allows them to join other proteins and form the 
inhibitory DREAM complex. As the cells progress through the cell cycle, activated cyclin/CDK 
progressively phosphorylate p130/p107 causing their deactivation and subsequently DREAM complex 
disassembly. Additionally, and importantly the transcriptional activators B-MYB and later FOXM1 
displace the transcriptional repressors p130/107 and E2F. MuvB association with B-MyB or FOXM1 
switches the DREAM complex to B-MYB-MuvB complex (MMB), FOXM1-MMB complex or FOXM1-MuvB 





Not only the levels of PLK1, but also its protein kinase activity is cell cycle 
regulated, which increases during G2/M transition and peaks in mitosis. Several 
hours prior to mitosis, CDK1 phosphorylates Bora (a cofactor of Aurora A). This 
promotes the PLK1-Bora interaction at PLK1 PBD which causes conformational 
changes to PLK1 structure. As a result Aurora A can phosphorylate PLK1 at its 
T loop (T210) and activate it (Macůrek et al., 2008; Seki et al., 2008).  
PLK1 levels and activity decreases at the end of mitosis. CDH1 (APC/C 
activator) recognises and binds to PLK1 D-Box (destruction Box) and activates 
APC/C. Activated APC/C then targets PLK1 for degradation by 26S proteasome 
(Lindon and Pines, 2004). 
1.2.6 PLK1 in DNA damage response 
Cells are constantly undergoing endogenous or exogenous DNA damage 
which, if not repaired, could cause genetic instability. Cells undergoing DNA 
damage in interphase, particularly in S and G2 phase, cause activation of the 
G2 checkpoint and cell cycle arrest (Checkpoints will be explained in section 
4.1.1) (Hyun, Hwan and Jang, 2014). PLK1 has been suggested to be a target 
for G2/M checkpoint in response to DNA damage as cells containing 
constitutively active mutants of PLK1 (T210D or S137D/T210D) can override 
the DNA damage activated checkpoint (Smits et al., 2000).  
In response to DNA damage ATM/ATR phosphorylate Bora at threonine 501. 
This phosphorylation subjects Bora for recognition by an E3 ubiquitin ligase 
(SCF-β-TRCP) and causes its degradation. As a result, PLK1 cannot be 
phosphorylated and activated by Aurora A (Qin et al., 2013). After restoration of 
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DNA damage, PLK1 activity is required for checkpoint recovery and resetting 
the cell cycle (Macůrek et al., 2008). One of the mechanisms involves PLK1 
mediated regulation of a kinase protein called MFP (mitosis promoting factor). 
MPF consists of a catalytic subunit called cdc2 (also known as CDK1) and an 
activation subunit called cyclin B1 and stimulates mitotic entry (Nigg, 2001). 
PLK1 phosphorylates and activates CDC25c, which is an activator of cdc2, and 
also enhances the nuclear import of cyclin B1 eventually leading to mitotic entry 
(Gheghiani et al., 2017).   
Downregulation of PLK1 activity in response to DNA damage has been reported 
in mitosis too, where PLK1 is already activated. This mechanism is ATM/ATR 
dependent and involves dephosphorylation of PLK1 at threonine 210 by protein 
phosphatase 2A (PP2A) (Jang et al., 2007). 
 DNA damage not only affects the activity of PLK1, it also represses PLK1 
protein and mRNA levels in a p53 dependent manner (McKenzie et al., 2010).  
1.2.7 PLK1 and p53 
PLK1 and p53 interact with each other in a negative feedback loop (Figure 1-4). 
In response to DNA damage, p53 has been reported to downregulate PLK1 by 
direct and indirect mechanisms. p53 has been shown to repress the PLK1 gene 
expression by direct binding to the PLK1 promoter at p53REs (McKenzie et al., 
2010). p53 has also been suggested to repress PLK1 indirectly by inducing its 
downstream effector, p21. p21 inhibits cyclin/CDK and results in the formation 
of DREAM complex which is a repressor of PLK1 (Fischer, Quaas, Nickel, et al., 
2015). p21 has also been shown to repress PLK1 by disrupting the interaction 
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between cdk2 and NF-YA. NF-YA then binds to p21 and anchors it to CCAAT 
box resulting in PLK1 transcriptional repression (Lin et al., 2014). p53 has also 
roles in repression of FOXM1, an oncogenic transcription factor that acts in a 
positive feedback loop with PLK1 (Barsotti and Prives, 2009, Pandit, Halasi and 
Gartel, 2009). PLK1 repression has also been reported by p53 interaction with 
E2F1 to form an inhibitory p53–E2F1–DNA complex on the PLK1 promoter 
leading to suppression of E2F1 mediated PLK1 expression  (Zhou et al., 2013).  
On the other hand, PLK1 also inhibits the function of p53 both directly and 
indirectly. Ando and colleagues showed that, PLK1 physically interacts with and 
phosphorylates p53. This results in loss of p53 transactivation activity and pro-
apoptotic functions through inhibition of p53 mediated expression p21 and 
apoptosis inducing genes such as BAX (Ando et al., 2004). PLK1 can also 
indirectly inactivate p53 by promoting its degradation. Phosphorylation of serine 
260 of MDM2 by PLK1 may contribute to MDM2 stabilisation and binding to 
p53, thereby promoting p53 degradation (Dias et al., 2009). Also, PLK1 by 
activation of CDC25C causes dephosphorylation of p53 at serine 15, which 
again increases the affinity of MDM2 to bind to p53 and promotes MDM2-
mediated turnover of p53 (Chen et al., 2006). PLK1 has been shown to 
phosphorylates Topors (topoisomerase I-binding protein) at serine 718, leading 
to enhancement of p53 ubiquitination and degradation (Yang et al., 2009).  
These evidences indicate the presence of a negative feedback loop between 
p53 and PLK1, with p53-mediated repression of PLK1 transcription and PLK1-
mediated inhibition of p53 function and promotion of its degradation. As the 
focus of chapter 3 of this thesis is the repression of PLK1 by p53, the next 







Figure 1-4. Negative feedback loop between PLK1 and p53. 
There is a negative feedback loop between PLK1 and p53, with PLK1 mediating inhibition of p53 function 
and promoting its degradation and p53 mediating PLK1 repression. Different mechanisms, illustrated in 





p53 was first discovered in 1979 by several independent groups as a protein of 
approximately 53 KDa that was found bound to the Simian Virus 40 Large T-
antigen (a known oncogene) (Lane and Crawford, 1979; Linzer and Levine, 
1979; Kress et al., 1979). p53 was then reported to be highly expressed in 
transformed cells compared to untransformed cells. However after irradiation, 
untransformed cells underwent a rapid increase in p53 levels which was 
attributed to post translational stabilization of p53 (Maltzman and Czyzyk, 
1984). p53 was then found to be localised in the nucleus of the transformed 
fibroblast cells but in the cytoplasm of untransformed fibroblasts. Based on the 
above reports, the first decade of p53 research, pointed to p53 as an oncogene 
(Rotter, Abutbul and Ben-Ze’ev, 1983).  
However, later it was discovered that the cDNAs used in initial experiments 
encoded mutant forms of p53 and although mutant p53 could cause 
transformation of cells, wild type p53 could suppress transformation (Finlay, 
Hinds and Levine, 1989). Since then, the main focus of research on p53 has 
been on its tumour suppressive role and it has been regarded as “guardian of 
the genome” by one of its founders (Lane, 1992).  
1.3.1 p53 structure 
p53 is a homo-tetramer and contains 393 amino acids. The structure of p53 has 
been shown in Figure 1-5. In order to perform its functions, p53 requires 
multiple domains which can be divided into three groups: N-terminal domain, 











Figure 1-5. Structure of p53 protein.  
Schematic represents important domains of p53 protein. TAD1 and TAD2 are transcriptional activation 
domains, PRR is the proline rich region, NLS is nuclear localisation sequence, TD is tetramerisation 






The N-terminal domain consists of 2 transactivation domains (TAD1 and 
TAD2) and a proline rich region (PRR). The transactivation domains are 
required for p53 to function as a transcription factor (Fields and Jang, 1990). 
The proline rich region has been reported to be required for growth 
suppression, apoptosis and response to ionising radiation (Campbell et al., 
2013). 
The core domain is responsible for site/sequence specific DNA binding of p53 
to its target genes at sequence specific elements, termed p53 responsive 
elements (p53REs). The majority of cancer-related mutations in the TP53 gene 
(encoding p53)  occur within this region and are generally missense mutations 
(Vousden and Lu, 2002). Six hotspot mutations on this domain have been 
identified. Three of these mutations are ‘conformational’ mutants which affect 
the residues that stabilise the tertiary structure of DNA binding surface (Arg 175, 
Gly245 and Arg 249). The other three are ‘contact’ mutations that affect the 
residues necessary for making direct contact with DNA (Arg 248, Arg 273 and 
Arg 282) (Olivier, Hollstein and Hainaut, 2010; Freed-Pastor and Prives, 2012). 
Mutations at these sites not only cause loss of wild type p53 functions, but also 
can cause gain of novel oncogenic functions (Muller and Vousden, 2013). 
The C-terminal domain comprises sequences for smaller domains and 
elements. These are nuclear localisation signal, tetramrisation domain and C-
terminal regulatory domain. Nuclear localisation signal as the name indicates is 
required for the localisation of p53 into nucleus. Tetramerisation domain 
mediates formation of homo and hetero tetramers which are crucial for p53 to 
perform DNA binding, protein-protein interactions, post translational 
modification (PTM) and p53 degradation. The C-terminal domain has also been 
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reported to have a nuclear export signal that regulates p53 degradation (Chène, 
2001). The regulatory domain is an important region for a variety of post 
translational modifications and p53 non-specific binding (Jayaraman and Prives, 
1999).  
1.3.2 p53 regulation 
In unstressed conditions, the cellular levels of p53 are low and the protein 
undergoes rapid turnover. However, in the event of cellular stresses (DNA 
damage, hypoxia, telomere erosion, mitotic catastrophe, oncogene activation, 
etc.) p53 levels increase. This rapid increase could result in different cellular 
responses such as cell cycle arrest and/or apoptosis.  
The main negative regulator of p53 is the ring finger E3 ubiquitin ligase MDM2 
(mouse double minute 2). A MDM2 docking site in the transactivation domain of 
p53 enables specific interaction of p53 and MDM2. This allows MDM2 to 
ubiquitinate p53 and transport it to cytoplasm for degradation. MDM2 mediated 
regulation of p53 is part of an auto regulatory negative feedback loop 
mechanism. The promoter region of the MDM2 gene contains a p53RE which 
enables active p53 to induce the expression of its own inhibitor (Honda and 
Yasuda, 2000). Negative regulation of p53 activity by MDM2 has been shown in 
mouse models. MDM2 knockout mice are embryonically lethal due to excess 
apoptosis. The lethality is rescued when p53 is knocked out too (Luna, Wagner 
and Lozano, 1995). 
p53 is tightly regulated by MDM2 and uncoupling/preventing the MDM2-p53 
interaction is universally required for p53 stabilisation and activity. This can be 
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done in several ways. ARF (alternative reading frame) is a protein that, upon its 
expression, binds to MDM2 central acidic domain and  inhibits its ubiquitin 
ligase function leading to p53 stabilisation (Luna, Wagner and Lozano, 1995). 
ARF can also sequester MDM2 within the nucleolus, in a physically separate 
compartment, thereby activating p53 in nucleoplasm (Weber et al., 1999).  
DNA damage-induced phosphorylation of MDM2 is another example by which 
MDM2 mediated ubiquitination of p53 is disturbed. In response to DNA damage 
(IR), ATM phosphorylates MDM2 at serine 395 which inhibits nuclear export of 
p53 by MDM2. This leads to accumulation of p53 (Maya et al., 2001).  
Apart from ubiquitination, p53 undergoes a wide range of other PTMs which 
play important roles in p53 regulation. One of the key events disturbing the 
MDM2-p53 interactions, is phosphorylation of p53. In the event of cellular 
stress, p53 is phosphorylated at its transactivation domain (including serine 15, 
Threonine 18 and serine 20). This causes conformational changes in p53 and 
inhibition of MDM2 binding. p53 phosphorylation at serine 15 has been reported 
to cause conformational changes in p53, reducing its interaction with MDM2 
and increased levels of p53 (Shieh et al., 1997). Role of serine 20 
phosphorylation in stability of p53 has been documented too. Mutation of serine 
20 to an alanine in p53 led to high sensitivity of p53 to degradation by MDM2 in 
response to IR and UV light (Chehab et al., 1999). However, another group 
have reported that phosphorylation of p53 at threonine 18, but not serine 15 
and/or serine 20, significantly weakens binding affinity of MDM2 to p53 (Schon 
et al., 2002). It has also been documented that phosphorylation of residues in 
p53 N-terminus (serine 15, 33, 37), as the result of cellular stresses, can 
stabilise p53 binding to p300 and CREB-binding protein (p300/CBP) (Dumaz 
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and Meek, 1999; Lambert et al., 1998). The transcriptional factor acetyl 
transferase activity of p300/CBP can acetylate p53 at residues required for 
MDM2 mediated ubiquitination of p53 which results in abrogation of 
ubiquitination by MDM2 and stabilisation of p53 (Li et al., 2002).  
There are many mechanisms/proteins involved in p53 regulation and its 
stabilisation in response to different types of cellular stresses which varies 
depending on the nature of stimuli and cell type. DNA damage is one of the best 
and most studied triggers of p53 pathway. 
1.3.3 p53 pathway and DNA damage   
ATM and ATR have an important role in stabilisation of p53 in response to DNA 
damage. As discussed in the previous section, DNA damage induced-
phosphorylation of MDM2 leads to uncoupling of MDM2-p53 and p53 activation. 
ATM and ATR can phosphorylate p53 at serine 15, a key event in transcription 
of p53 regulated genes such as p21 (Loughery et al., 2014). Not only ATM and 
ATR but also DNA-PK (DNA dependent protein kinase) has been suggested to 
phosphorylate p53 at serine 15 and 37 in response to DNA damage (Lees-Miller 
et al., 1992).  
DNA damage also results in phosphorylation of p53 at serine 20 by Chk1 and 
Chk2 (downstream targets of ATR and ATM respectively) (Shieh et al., 2000). 
Another activator of p53 is p38, belonging to the MAPK (mitogen activated 
protein kinase) family. In response to UV radiation, p38 phosphorylates p53 at 
serine 33 and 46 leading to p53 activation (Bulavin, 1999).  
p53 activation is responsible for regulating many genes ultimately leading to cell 
cycle arrest, senescence or apoptosis depending on the level of the damage. 
31 
 
The cell cycle arrest itself could either be permanent or temporary until the 
damage is repaired.  
1.3.4 p53 as a transcription factor  
As a transcription factor p53 can mediate transcription of different genes critical 
for control of the cell cycle and induction of apoptosis (Appella and Anderson, 
2001).  p53 has been suggested to cause both transactivation and repression of 
its target genes. The transactivation role of p53 is better known and studied. 
The main mechanism by which p53 transactivates genes is by direct binding to 
sequence specific DNA sites called p53 responsive elements (p53REs) 
(Sullivan et al., 2017). p53-mediated gene repression has been suggested to 
occur by both direct and indirect mechanisms (Riley et al., 2008). However, 
more recent analysis has suggested that p53 is solely an activator and the 
repression of genes by p53 could happen only through indirect mechanisms 
(Fischer, Steiner and Engeland, 2014).  
PLK1 is one of the genes that has been reported to be a target of p53 
transcriptional repression. Before explaining different mechanisms reported for 
PLK1 repression by different laboratories (which will be discussed in section 
3.1), a brief introduction is given below about different elements/proteins that 
are involved in p53-mediated transcriptional activation and repression.  
TATA box binding protein (TBP): TATA box is a sequence in the promoter of 
some genes and indicates (to other proteins) where transcription should initiate. 
It is generally about 30 base pair (bp) upstream of transcription start site (TSS) 
and is present in only 10 to 20% of human genes (Kornberg, 2007). It is a 
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binding site for TATA box binding protein (TBP) and consequently the 
transcription factor TFIID complex (consists of TBP and several subunits called 
TATA binding protein associated factors (TAFs) such as TAF1 and TAFII250) 
(Hernandez, 1993, Burley and Roeder, 1996). TFIID complex will make part of 
the RNA polymerase II pre-initiation complex and helps in positioning RNA 
polymerase II over the TSS (Hernandez, 1993). It has been documented that 
p53 binds to TBP forming p53-TBP complex. The complex can then directly 
bind to TATA box and promote binding of RNA polymerase and initiate 
transcription (Seto et al., 1992; Martin et al., 1993; Chen et al., 1993)    
CCAAT box binding factor (CBP/NF-Y): The CCAAT box is one of the most 
prevalent elements in the promoter of eukaryotic cells and its mutation has been 
documented to cause several fold decrease in transcriptional activity (Maity and 
De Crombrugghe, 1998). It has been suggested that in TATA-less promoters, 
there is increased occurrence of CCAAT boxes (Mantovani, 1998). The main 
protein recognising and binding to this box is NF-Y (nuclear transcription factor 
Y) (Mantovani, 1999). NF-Y is composed of three subunits; NF-YA, NF-YB, NF-
YC. (Maity and De Crombrugghe, 1998). It interacts with different transcription 
factors and also to histone acetyl transferases (Mantovani, 1999). NF-Y is 
essential for the recruitment of RNA polymerase II to several CCAAT box 
containing promoters (Kabe et al., 2005).  
NF-Y and CCAAT boxes are important not only for transactivation of genes but 
also for their repression in the event of DNA damage. It has been reported that 
p53 can repress promoters of key regulators of the G2/M transition (such as 
cdc2, cyclin B and CDC25C) by its interaction with NF-Y and CCAAT boxes. 
p53 rapidly undergoes acetylation following DNA damage. This leads to 
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recruitment of histone deacetylases on G2/M promoters, deacetylation of 
histones and release of P300 and PCAF which coincide with repression of the 
promoters. This can then result in checkpoint arrest (Imbriano et al., 2005). 
Indirect p53 repression of genes through this box has been suggested too. The 
model proposed by Lin et al, indicates that in unstressed cells CDK2 
phosphorylates nuclear factor YA (NF-YA) subunit of the CCAAT box which is 
responsible for sequence specific DNA binding. This association facilitates 
binding of NF-Y and CCAAT box and enables transactivation of PLK1 which is 
necessary for cell cycle progression. In stressed conditions on the other hand, 
activated p53 induces p21. p21 then displaces CDK2 in interacting with NF-YA 
so there will be less association of CDK2 and NF-YA. This leads to CCAAT box-
associated regulatory complex to have repressive function presumably with 
recruitment of co-repressors or HDACs (Lin et al., 2014). 
Specificity protein 1 (SP1): SP1 is a transcription factor that binds to the GC 
box (GC rich motif) of many promoters. The activity of SP1 as a transactivator 
or repressor, is affected by post translational modifications. p53 has been 
shown to have a strong cooperation with SP1 in regulation of several tumour 
suppressor and oncogenes. This cooperative regulation of transcription by p53 
and SP1 varies between genes. Some studies show that they work together to 
promote transcription while in other instances they demonstrate opposing 
effects on transcription (Beishline and Azizkhan-Clifford, 2015).  
E2F binding site: E2F is a family of transcription factors which bind to the 
promoter sequences called E2F binding sites. They have been recognised as 
regulators of transcription of the cell cycle-dependent genes with maximal 
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expression in S phase. Depending on which member of E2F family bind to the 
consensus element, the outcome could be activation or repression of the gene 
(E2F1-3 are activators while F2F4-5 are repressors) (Slansky and Farnham, 
1996; Helin, 1998).  
p53 can repress genes indirectly through E2F binding sites. It involves p21 
upregulation and subsequent CDK1 inhibition which leads to hypo-
phosphorylation of p130/107 and formation of inhibitory DREAM complex 
(Müller et al., 2012; Litovchick et al., 2007). Müller et al. showed that in genes 
mainly expressed in S phase, DREAM binds to E2F sites and the binding can 
be supported by interaction of LIN54 of MuvB core complex with elements 
called CHR like elements (CLE) positioned 4 bp downstream of E2F binding site 
which differ in one or 2 nucleotides from the consensus (Müller et al., 2016).  
CDE/CHR elements: As mentioned in section 1.2.5, The cell cycle-dependent 
element (CDE) and the cell cycle genes homology region (CHR) are elements 
found in the promoter of cell cycle dependent genes with maximal expression in 
G2/M. CDE/CHR are responsible for negative regulation of these genes early in 
cell cycle and mutation of either of these elements results in activation of 
transcription and loss of cell cycle regulation of these genes (Zwicker et al., 
1995; Badie et al., 2000). However, the CDE function has been suggested to be 
secondary to CHR function (Müller et al., 2012). CDE sites are in fact special 
E2F binding elements and share similar sequences with them but what 
distinguishes CDEs is that CDEs are only 4 nucleotides upstream of CHR 
elements. CDE/CHR containing promoters usually lack a TATA box and contain 
multiple CCAAT boxes (Müller and Engeland, 2010). 
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p53 mediates downregulation of genes expressed in G2/M in response to 
stresses and one of the mechanisms suggested is through CDE/CHR. (Müller 
and Engeland, 2010). The mechanism is similar to the suggested mechanism 
for E2F binding sites which involves upregulation of p21 by p53 and formation 
of DREAM complex which binds to CDE/CHR elements (Müller et al., 2012; 
Litovchick et al., 2007) . These events could lead to gene repression. p53 has 
also been reported to mediate downregulation of CDC25C through CDE/CHR 
elements but independently of p21 as p53 could still repress the promoter in the 
HCT116 p21 null cells (Clair et al., 2004).  
 
Despite nearly 40 years of research and an ever-growing number of 
publications on p53 (around 90000 listed in PubMed), its central role as a 
transcriptional regulator has not yet been understood completely. How p53 acts 
as a transcriptional activator for one target gene and repressor for another, 
remains to be resolved. There has been enormous amount of discoveries in p53 
field, but the picture is not complete yet. Additionally, some scientists have 
suggested that p53 could act as both transcriptional activator and repressor and 
some others believe p53 is solely an activator.  
As explained before, several elements/factors have been identified which are 
involved in p53 regulated transactivation and/or repression. Importantly, there 
has been some apparently contradictory data reported by different groups, for 
some genes. For example, in case of PLK1 repression by p53, several 
mechanisms have been reported by different groups which seems conflicting. 
This made the basis of our investigations in chapter 3 of this thesis. The 
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mechanisms suggested for PLK1 repression by p53 will be discussed later in 
the background of the chapter 3 (section 3.1). 
1.4 Thesis Aims 
Given the importance of PLK1 in proliferation and its many functions especially 
during mitosis, importantly the high dependency of cancer cells to PLK1, there 
are two critical areas where further analysis would provide better understanding 
of how this protein functions and regulated. These are stated in the following 
aims: 
 To investigate whether the recently proposed universal model of p53 
mediated repression through regulating DREAM complex explains p53-
mediated PLK1 repression in a satisfactory manner or whether other 
mechanisms may additionally operate, either through cooperating with 
DREAM or independently of DREAM perhaps in a context-dependent 
manner. 
 Knowing the important functions of PLK1 in mitosis, attempt to bring 
more insight into the consequences of pharmacologically inhibiting PLK1 
in mitosis. Also, to investigate if there are differences between the 
consequences of mitotic inhibition by PLK1 inhibition and that induced by 









Chemical Name Manufacturer Catalogue No. Use 
BI2536 Selleck chemicals S1109 PLK1 inhibitor 
Cisplatin Sigma Aldrich 479306 
interferes with DNA 
replication 
Doxorubicin Sigma Aldrich 25316-40-9 





Etoposide Selleckchem S1225 
Topo-isomerase II 
Inhibitor 
Geneticin (G418) Life Technologies 108321-42-2 
Antibiotic (selection for 
stable lines) 
Hygromycin B Life Technologies 31282-04-9 
Antibiotic (Selection of 
stable lines) 
KU55933 Sigma Aldrich SML1109 ATM inhibitor 
Nocodazole Calbiochem 487928 
Prevents microtubule 
polymerisation 
NU6027 Sigma Aldrich N4411 ATR inhibitor 
NU7441 Tocris 3712 DNA-PKc inhibitor 
Nutlin-3a Tocris 3984 
Inhibits the interaction 




ZM 447439 Selleckchem S1103 AuroraB inhibitor 




Sigma Aldrich B9285 Thymidine analogue 
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2.3 Reagents and Buffers 




Immuno-Fluorescence (IF) Reagents and Buffers: 
Antibody dilution buffer 
20 mM Tris pH7.5 
150 mM NaCl 
2% (w/v) BSA 
2% (w/v) marvel 
0.2% (w/v) fish gelatine 
0.1% (v/v) triton X100 
KCM buffer: 
120 mM KCL 
20 mM NaCl 
10 mM Tris pH 7.5 
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0.1% (v/v) triton X100 
Hypotonic buffer: 
20 mM Hepes pH 7 
1 mM MgCl2 
20 mM KCL 
10 µl 1M CaCl2  
PNA hybridisation solution: 
70% (v/v) deionised formamide 
0.25% (v/v) blocking reagent 3GM  
10 mM Tris pH7.5 
4 mM Sodium orthophosphate 
0.5 mM citric acid 
12.5 mM MgCl2 
PNA wash A: 
70% (v/v) deionised formamide 
10 mM tris pH 7.5 
PNA wash B: 
50 mM tris pH 7.5 
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150 mM NaCl 
0.08% Tween 20 
 
Western Blotting Reagents and Buffers 
Enhanced chemiluminescence (ECL) solution 1 
2.5 mM Luminol 
100 mM Tris (pH 8.5) 
396 μM P-Coumaric Acid 
Enhanced chemiluminescence (ECL) solution 2 
0.0192% (v/v) H2O2 
100 mM Tris (pH 8.5) 
Ponceau S staining buffer 
0.2% (w/v) Ponceau S  
5% glacial acetic acid 
SDS protein sample buffer (2X)  
0.125M Tris-HCl (pH 6.8) 
20% (v/v) Glycerol 
4% (w/v) SDS 
46 
 
0.02% (w/v) Bromophenol Blue 
Sodium Dodecyl Sulfate-polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Running Buffer (10X) 
250 mM Tris 
1.92 M Glycine 
1% (w/v) SDS 
Western Blot Blocking Buffer and antibody dilution buffer 
1X PBS 
0.1% (v/v) Tween 20 
5% (w/v) Marvel Dried Milk 
Western Blot Transfer Buffer 
25 mM Tris  
192 mM Glycine 
20% (v/v) Methanol 
Western blot washing buffer 
1X PBS 




Flow Cytometry Reagents and Buffers 
Propidium iodide staining buffer 
50 μg/ml Propidium Iodide  
200 μg/ml RNase A 
1X PBS 
Antibody dilution buffer for flow cytometry 
1x PBS 
0.5% (w/v) Bovine Serum Albumin (BSA) 
0.5% (v/v) Tween 20 
2.4 Cell Culture and Related Methodologies 
2.4.1 Cell culture maintenance 
Stocks of all cell lines were available in the laboratory (see table 2.4 for 
sources) and were grown in Dulbecco’s Modified Eagles Medium (DMEM) 
(GIBCO) supplemented with 10% fetal bovine serum (FBS, Biosera (Labtech 
International Ltd.)) and 2 mM L-glutamin (Gibco) and were maintained at 37°C 
in a humidified atmosphere set at 5% CO2. When cells were about 70-90% 
confluent, media was aspirated, adherent cells were washed twice with PBS 
and then trypsinised (using 0.05% trypsin-EDTA dissociation reagent) to detach 
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the cells from the flask. Detached cells were then re-suspended in media and 
sub-cultured. 
 
































*Dr. Vogelstein, Johns Hopkins University, USA 
Table 2.4 Mammalian cell lines used 
 
2.4.2 Cryopreservation of cells  
Cells were seeded in a 175 cm2 flasks and when they reached about 80% 
confluency, they were trypsinised and re-suspended in media. The suspension 
was then centrifuged at 300 xg for 5 minutes to obtain the pellet. After 
centrifugation, growth media was aspirated, and pellet was re-suspended in 5 
ml of ice-cold freezing media. Cell suspension (1ml) was then transferred to 
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each cryogenic vials (corning). Vials containing cells were then transferred to an 
insulated polystyrene box to ensure slow freezing and were then transferred to -
80°C freezers for a few days before transferring them to liquid nitrogen for long 
term storage. 
2.4.3 Revival of cryopreserved cells 
Cryogenic vials were taken from liquid nitrogen and placed in dry ice. Vials were 
then placed in a water bath set at 37°C for a quick thaw. Cell suspension was 
then transferred to pre-warm growth media (37°C). Cells were then centrifuged 
at 300 xg, media was aspirated, and pellet were re-suspended in fresh media 
and transferred to a flask and incubated in 37°C, 5% CO2 in humidified 
atmosphere.  
2.4.4 Cell counting and seeding 
Trypsinised cells were pooled together and re-suspended in media. 10 µl of this 
suspension were loaded to each side of a haemocytometer (Hawksley, Sussex, 
UK, 1/400 m2). Cells were then counted under microscope using a M45 Hand 
Tally (ENM counting instrument, Chicago, USA) and seeded as required.  
2.4.5 Drug treatments 
Cells were seeded at the appropriate density according to the size of the plate 
or dish and incubated overnight in 37°C, 5% CO2, in humidified atmosphere. 
Following overnight incubation different concentrations of drugs were added to 
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the cells and incubated for further 24 hours. As control, cells were either 
untreated or treated with 0.1% dimethyl sulfoxide (DMSO, used as the vehicle 
for drugs), in case DMSO alone has any effect on the cells.  
2.4.6 Transient DNA transfections 
Cell lines to be transfected were seeded in appropriate density (around 60% 
confluent at the time of transfection) and incubated overnight before 
transfection. Transfection with plasmid DNA was then carried out using either 
FuGENE HD (Promega) or Lipofectamin 2000 (Invitrogen). Where different 
amounts of a gene were added, the volume topped up with empty vector so that 
there is equal amount of the plasmid transfected in all conditions of an 
experiment. Transfected cells were then incubated for another 24 hours before 
1X passive lysis buffer (Dual Luciferase Reporter Assay System, Promega) was 
used to lyse the cells. Each transfection was carried out in triplicate.  
2.4.7 Gene silencing using siRNA 
Cells were transfected with siRNA by reverse transfection using Lipofectamine® 
RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s 
protocol. The siRNAs used are given in table 2.5. In each 6 well dish 1.5 µl of 
20 µM siRNA oligo was added to 500 µl Opti-MEM and mixed gently. 5 µl 
RNAiMAX was then added to each well and incubated for 20 minutes at room 
temperature. 2.5x105 cells suspended in 2.5 ml of media was added to each 
well following 20 minutes incubation and mixed to distribute evenly. Cells were 
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then incubated for 24 hours before further experimentation carried out. Non-































Table 2.5 List of siRNAs used. 
 
2.4.8 Luciferase reporter assay 
Cells were seeded in 12 or 24 well plate at appropriate density and transfected 
using FuGENE HD or Lipofectamine 2000. Cells were transfected with a pGL3 
plasmid in which 2.4 Kb of the human PLK1 promoter was cloned upstream of 
the firefly luciferase gene. Transfected cells were incubated for 24 hours before 
any further experimentation carried out. Cells were harvested 24 hours after 
treatments using passive lysis buffer (Promega). Dual luciferase reporter assay 
system (Promega) was used to analyse 20 µl of protein extracts in each well of 
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a 96 well plate by luminometer (GloMax®-Multi Detection System (Promega)). 
Transfection efficiencies were normalised by using Renilla luciferase activity of 
the extracts or by doing protein quantification using DC (detergent compatible) 
assay followed by western blot analysis to check the efficiency of the 
transfection. 
2.4.9 Construction of stable lines 
U2OS cells were seeded at the density of 4x104 cells/well in a 6 well plate. 
Following overnight incubation cells were treated with either pGL3 plasmid 
(basic, Promega) or pGL3 plasmid in which 2.4 kb of the human wild type PLK1 
promoter or PLK1 promoter that is mutated at CDE/CHR elements cloned 
upstream of the firefly luciferase gene (figure 2.1). pcDNA3 plasmid was co-
transfected at the ratio of 1:10 (pcDNA3:pGL3) as a selection marker as it 
(pcDNA3) has a G418 resistant gene. Cells were kept in media containing G418 
(400 µg/ml) until surviving cells formed colonies. Colonies were then isolated 
and re-plated in media containing G418. After cells reached enough confluency, 















Figure 2-1.  Schematic representation of the different constructs cloned in pGL3 plasmids and 
transfected into the cells.  
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2.4.10 Mitotic wash off and preparation of metaphase spreads 
Cells were seeded and incubated overnight at 37ºC. Cells were then 
synchronised by nocodazole/PLK1 inhibitor for 2 hours. Mitotic shake off was 
carried out to collect the mitotic cells. This was done by applying slight 
mechanical force, by pipetting up and down the media, to separate the loosely 
attached rounded up cells. Rounded up cells/floating cells in the growth media 
were then collected, leaving adherent cells behind. Following this, pre-
synchronised cells were either pelleted and processed for further 
experimentation or re-plated in nocodazole/PLK1 inhibitor for a prolonged 
mitotic arrest (further 2 or 4 hours). Normal mitotic cells were collected from 
untreated asynchronous cells. Cell suspension was then centrifuged at 300 xg 
for 4 minutes at room temperature. Mitotic cell suspension was then washed 
and centrifuged again, media was removed leaving around 50 µl behind. Cells 
were then suspended, in the remaining 50 µl of the media, and hypotonic buffer 
was added and mixed with gentle shaking (without the use of pipettes). Cell 
suspension in hypotonic buffer was incubated at room temperature for 10 
minutes.  
Using cytospin apparatus cells were then centrifuged onto super frost plus glass 
slides and centrifuged at 300 xg for 3 min after initial equilibrisation of the 
system which included loading 100 µl of 2% BSA in the cytospin and 
centrifuging for 1 min at 300 xg. Slides containing metaphase spreads were left 
on bench for about one minute to air dry and then were fixed using 4% 
formaldehyde in PBS for 10 minutes at room temperature. Slides were then 
rinsed few times with PBS and proceeded with next steps or stored in 4°C. 
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2.4.11 Clonogenic assay 
A549 or U2OS cells were seeded in appropriate density in 10 cm dishes and 
incubated overnight at 37ºC. Following overnight incubation cells were treated 
with nocodazole or PLK1 inhibitor. Mitotic shake off was carried out. Mitotically 
arrested cells were then counted and re-plated in fresh media at the density of 
1.5x103 cells per 10 cm dish. Dishes containing cells were then incubated for 9 
days when colonies reached desired size. Clonogenic assays were carried out 
by washing the dishes containing colonies twice with PBS. They were then fixed 
by exposing them with methanol for 10 min. Methanol was then aspirated from 
the plate and replaced with 0.4% crystal violet solution (made in 25% methanol) 
for staining. After 10 minutes, the crystal violet solution was aspirated. Plates 
were then immersed in running water and rinsed carefully until colour no longer 
come off in the rinse. Plates were then left to air dry and Number of survived 
colonies in each dish was then counted.  
2.5 Preparation and Quantification of Protein Samples 
Cells were washed twice with PBS and lysed by using 2X SDS page sample 
buffer using cell scrapers. Lysates were then sonicated for homogenisation for 
20 seconds at 30% amplitude. Total protein in each sample was quantified by 
DC assay kit (Biorad), according to manufacturer’s protocol. Briefly reagent A 
and S were mixed at the ratio of 50:1. 25 µl of the mix was then transferred to 
each well of a 96 well plate along with 17 µl of distilled water. 3 µl of lysates 
were then added to the wells and then 200 µl of reagent B added to all the wells 
containing lysates. Everything was conducted in duplicate. The plate was then 
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incubated for 15 minutes at room temperature in dark before absorbance was 
read at 750 nm using GloMax®-Multi Detection System (Promega).  
2.6 Separation of Proteins Using SDS-PAGE 
Prepared samples were heated at 90ºC for 5 minutes. Unless otherwise stated 
in the figure legends, 20 µg of proteins were loaded in appropriate percentage 
of acrylamide gels (table 2.6 and 2.7). PageRulerTM Plus Prestained Protein 
Ladder 10-250 KDa (Thermo Fisher Scientific) was loaded in gels adjacent to 
the samples to determine the molecular weight. Proteins were separated by 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), 
using a vertical Slab Electrophoresis Chamber Apparatus (Atto) and SDS-
PAGE running buffer. Electrophoresis was carried out using a power supply set 
at 100 V for the duration of the gel running. 
 
Reagents 8% 10% 12.5% 
Distilled water (ml) 3.95 3.3 2.475 
12.5 mM Tris-HCL pH 8.8 3 3 3 
30% (w/v) Acrylamide 0.8% (w/v) 
Bis-acrylamide stock solution 
(37:5:1) (ml) 
2.64 3.3 4.125 
10% SDS (µl) 100 100 100 
10% APS (µl) 100 100 100 
TEMED (µl) 10 10 10 
 
 




Reagents Volume Required 
Distilled water (ml) 2.15 
12.5 mM Tris-HCL pH 6.8 0.3 
30% (w/v) Acrylamide 0.8% 
(w/v) Bis-acrylamide stock 
solution (37:5:1) (ml) 
0.5 
10% SDS (µl) 30 
10% APS (µl) 25 
TEMED (µl) 2.5 
 
Table 2.7 Buffers and their quantity for stacking gels. 
 
2.7 Western Blot Analysis 
After separation of proteins by SDS-PAGE, proteins were transferred to a 
Hybound ECL nitrocellulose membrane (Amersham) using wet transfer 
apparatus (Bio-Rad) at 100 V for 1 hour. Membranes were then blocked in 
western blocking buffer for one hour at room temperature. They were then 
incubated in primary antibodies diluted in western blot antibody dilution buffer 
overnight at 4°C. Following 3 washes with PBS 0.1% Tween-20, appropriate 
horseradish peroxidase-conjugated secondary antibodies were added to the 
membranes and incubated for 1 hour at room temperature. Membranes were 
then washed 3 times, equal volume of ECL1 and ECL2 was then mixed and 
added to the membranes and proceeded for chemiluminescence detection 
using ChemiDoc™ MP Imaging System (Bio-Rad). 
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2.8 Cell Cycle Analysis 
Cells were seeded in appropriate density and incubated overnight at 37ºC. Cells 
were then treated with different agents as indicated in each experiment and 
incubated for 24 hours. Cells were labelled with 30 µM BrdU and incubated in 
37ºC for 30 minutes. BrdU is a thymidine analogue and labels newly 
synthesized DNA in S phase. A non-BrdU labelled sample was prepared as well 
as a control. Both floating and adherent cells were collected. Cell pellet was 
prepared using centrifugation at 300 xg for 5 minutes. Cells were then re-
suspended in PBS to wash and pelleted again before re-suspending them in 1 
ml of PBS. Cells were then fixed by adding 3 ml of 100% ice cold ethanol 
dropwise while vortexing. Fixed cells were incubated in 4 ºC for maximum of 2 
weeks. 
3-4 ml PBS supplemented with 1% FBS was added to the cells and centrifuged 
for 5 minutes. The pellet was then washed with PBS-FBS and centrifuged. This 
time cells were treated with 1 ml of 2 M HCl and incubated for 20 minutes at 
dark in a water bath set at 37ºC. Occasional mixing was carried out during 
incubation. Wash step with PBS-FBS was then performed twice. Pellets were 
re-suspended in 200 µl Beckton Dickinson anti BrdU antibody (BD Bioscience, 
Oxford, UK) diluted 1:50 in antibody buffer and incubated for 1 hour at room 
temperature in dark with occasional shaking.  
Cell suspension was washed with PBS-FBS and pelleted again. Pellet was re-
suspended in 200 µl of FITC conjugated anti mouse IgG (whole molecule) 
antibody diluted to 20 µg/ml in antibody dilution buffer (1:64 dilution) followed by 
incubation for 30 minutes.  
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Cell wash step with PBS-FBS was repeated and pellets were re-suspended in 
300 µl propidium iodide staining buffer. Cell suspension was then transferred to 
FACS tubes and incubated at room temperature in the dark for 20 minutes 
before analysis or stored at 4ºC overnight for analysis by flow cytometer (BD 
Biosciences). Flowjo software was then used for the analysis of the cell cycle. 
2.9 Immuno-Fluorescence Studies and Microscopy 
Cells or metaphase spreads were fixed in 4% formaldehyde in PBS for 10 
minutes at room temperature and rinsed in PBS. Cells were permeabilised with 
KCM buffer for 10 minutes and then blocked for 20 minutes at 37°C. Cells were 
then incubated overnight at 4°C in primary antibodies diluted in blocking buffer. 
Following three 5 minutes washes with 0.1% Tween-20/PBS secondary 
antibodies and DAPI were added in blocking buffer and incubated for 1 hour at 
room temperature in the dark. Then cells were washed 3 times for 5 minutes 
with 0.1% tween-20/PBS and mounted using mounting media (DAKO). Images 
of the cells were taken by using a Leica SP5II laser scanning confocal 
microscope with a HCX Pl Apo CS 63 × 1.4 lens. Minimum of 25 cells were 
analysed per treatment. 
2.10 Fluorescence in Situ Hybridisation (FISH) 
Fluorescence in situ hybridisation (FISH) using PNA probe was used for 
telomere detection after γ-H2AX staining where needed. After 3 washes 
following secondary antibody, cells were fixed again in 4% formaldehyde in PBS 
for 10 minutes at room temperature. Fixed cells were then rinsed with PBS and 
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dehydrated by graded ethanol series, first with 70% ethanol for 3 minutes, then 
with 90% ethanol for 2 minutes and finally with 100% ethanol for 2 minutes. 
Slides were then air dried.  
Metaphase spreads were stained with PNA probe (Alexa 488–OO-
(TTAGGG)3 PNA probe, Panagene) in PNA hybridisation solution which has 
been preheated at 90ºC (1:100 of 100 nM probe, final concentration of 1 nM). 
Area of the slides containing metaphase spreads was then treated with PNA 
probe-PNA hybridisation solution and covered with an 18X18 mm coverslips. 
Slides were transferred to a pre-heated incubator at 80ºC for 10 minutes. Slides 
were then incubated at dark in room temperature for 2 hours for hybridisation.  
100 ml of PNA wash B was heated in microwave for 2 minutes and poured in 
coplin jar at 60ºC in the hybridiser with shaking. After 2 hours of incubation 
slides were washed in PNA wash A to remove the coverslips. Slides were then 
left in PNA wash A for 5 minutes. They were then washed in pre-heated PNA 
wash B at 60ºC in the incubator with shaking for 10 minutes followed by another 
wash with PNA wash B for 2 minutes at room temperature. Metaphase spreads 
were counter-stained with 250 ng/ml of DAPI in PNA wash B at room 
temperature for 10 minutes. Slides were then washed with PNA wash B for 5 
minutes at room temperature and rinsed with deionised water and mounted in 
mounting media (DAKO). Slides were progressed for imaging using a Leica 
SP5II laser scanning confocal microscope with a HCX Pl Apo CS 63 × 1.4 lens. 
Co-localisation between γ-H2AX foci and telomeres were analysed in minimum 
of 25 cells in each condition of an experiment.  
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2.11 Site Directed Mutagenesis 
Site directed mutagenesis was carried out using QuickChange Lightning Site 
Directed Mutagenesis Kit to introduce mutations at a specific sequence of the 
DNA, according to the manufacturer’s protocol. The plasmids in which 
mutations were introduced were PLK1 promoter in pGL3 basic plasmid and two 
truncated versions of it, one having a deletion in p53RE1 and another one 
deletion of both p53RE1 and p53RE2 (figure 2.2). Plasmids were previously 
prepared by a past member of our laboratory (Iyer et al., 2014). 
Newly prepared plasmids (with desired mutations) were sent for sequencing at 
the Tayside Centre for Genomic Analysis. The sequences were then analysed 


















For each reaction to be carried out, 100 ng of plasmid DNA was added to 5 µl of 
10X reaction buffer along with 125 ng of each forward and reverse primers 
(table 2.8). 1 µl of dNTP mix and 1.5 µl of QuikSolution reagent were added too 
and final volume was made up to 50 µl. 1 µl of QuikChange Lightning Enzyme 
was then added which is a derivative of PfuUltra high-fidelity DNA polymerase. 
PCR was then carried out as shown in Table 2.9. 
2 µl of the Dpn 1 restriction enzyme was added after the PCR cycles, mixed 
thoroughly and incubated at 37ºC for 15 minutes to digest the un-mutated 
parental (template) plasmid DNA. 2 µl of the digestion reaction was then 





















Segment Cycle Temperature (ºC) Time 
1 1 95 2 minutes 
2 18 
95 20 seconds 
60 10 seconds 
68 
30 seconds/kb of 
plasmid length 
3 2 68 5 minutes 
 
Table 2.9 PCR cycles used in mutagenesis. 
 
 
2.12 Transformation of Competent Cells 
45 µl of XL 10-Gold Ultracompetent cells were added to a pre-chilled 14 ml BD 
falcon polypropylene round bottom tube. 2 µl of XL 10-Gold β-mercaptoethanol 
(β-ME) mix was added and cells were incubated for 2 minutes on ice. 2 µl of 
Dpn 1 treated cells was added to the competent cells and mixed gently before 
incubating it on ice for 30 minutes. Following incubation, the cells were heat-
pulsed in a 42ºC water bath for 30 seconds and then incubated on ice for 2 
minutes. 500 µl of pre-heated (at 42ºC) S.O.C medium (Invitrogen) was then 
added to the tubes and incubated at 37ºC for 1 hour with shaking. 
After one hour of incubation, 100 µl of the transformation mix was spread evenly 
over LB-Agar plates containing Ampicillin. Following overnight incubation, 




2.13 Preparation of Mini-Preps 
QIAprep® Spin Mini-prep Kit was used to prepare mini-preps according to 
manufacturer’s protocol. 
2.14 Preparation of Maxi-Preps 
PureLink® HiPure Plasmid DNA Purification Kit from Invitrogen was used for 
maxiprep procedure. Following overnight growth of transformed E. coli in LB 
medium, centrifugation at 4000 xg was performed for 10 minutes. Pellet was 
then resuspended in 10 ml resuspension buffer containing RNase A. 10 ml of 
lysis buffer was then added, mixed gently, and incubated for 10 minutes. 10 ml 
of precipitation buffer was added next and mixed immediately by inverting the 
tube until a homogenous mixture obtained. Lysate was then centrifuged at 
12000 xg for 10 minutes at room temperature. The supernatant was transferred 
to an equilibrated HiPure Maxi Column and solution was allowed to be drained 
by gravity flow to allow binding of the DNA to the column. The column was 
washed with 60 ml of wash buffer and the flow through was discarded. A sterile 
50 ml centrifuge tube was placed under the column and 15 ml of elution buffer 
was added to the column and left to drain by gravity flow so that the purified 
DNA gets collected on the elution tube. Isopropanol was then added to the elute 
to precipitate the DNA. The tube was then centrifuged at 12000 xg for 30 
minutes at 4ºC. Supernatant was discarded, 70% ethanol was added to the 
pellet and centrifuged for 20 minutes at 4ºC. Supernatant was discarded, and 
pellet was allowed to air dry before resuspending purified plasmid in TE buffer. 
Plasmids were then stored in -20ºC until further use.  
66 
 
2.15 Glycerol Stocks 
Glycerol stocks were prepared by adding 800 µl of the overnight culture and 
300 µl of 100% glycerol to a cryovial. The cryovial was then stored at -80ºC. 
 
2.16 Statistical Analysis 
Where necessary to compare and determine the significance of differences 
between 2 samples, Student’s t-tests were performed. It compares the actual 
difference between two means in relation to the variation in the data (expressed 
as the standard deviation of the difference between the means). Results can be 






Chapter 3: p53-Dependent Repression of PLK1 is 






As mentioned in the introduction chapter (section 1.2.7), several studies have 
demonstrated downregulation of PLK1 following induction of p53 (McKenzie et 
al., 2010; Fischer; Quaas, Nickel, et al., 2015; Zhou et al., 2013; Lin et al., 
2014). Different mechanisms have been suggested by different groups for this 
downregulation. These are as follows.  
McKenzie et al suggested a direct mechanism; their chromatin immuno-
precipitation (ChIP) analysis showed that p53 recruits to p53 responsive 
elements in the promoter of the PLK1 in response to DNA damage or p53 
activation which causes downregulation of PLK1. They also found that histone 
deacetylases are involved in this process which further confirms that there is 
transcriptional repression mechanism (McKenzie et al., 2010) (Figure 3-1 A).  
More recently Fischer and colleagues showed that p21 is important in p53 
mediated repression of PLK1. They showed that CDE/CHR elements of the 
PLK1 promoter are needed for this repression. In this model p53 induced p21 
blocks the CDK-mediated phosphorylation of RB-related pocket proteins 
p107/130, keeping them in hypo-phosphorylated state. In this state, p107/130 
can join other proteins and form DREAM complex. Association of DREAM with 
CDE/CHR elements inhibits PLK1 transcriptional activation (Fischer, Quaas, 
Nickel, et al., 2015) (Figure 3-1 B). 
Other elements reported to be involved in PLK1 repression by p53 such as E2F 
binding sites. There are two potential E2F binding sites in addition to the 
CDE/CHR elements in PLK1 promoter. Zhou et al., 2013 showed that in 
response to cisplatin induced DNA damage, p53 interacts with E2F1 and forms 
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an inhibitory p53–E2F1–DNA complex on the PLK1 promoter and suppress 
E2F1 mediated PLK1 expression (Zhou et al., 2013) (Figure 3-1 C). On the 
other hand, another paper suggested that genes with maximal expression in 
G2/M have been suggested to be devoid of functional E2F binding sites (Müller 
et al., 2016). Also, Zhu et al. showed that E2F binding site deletions do not play 
a role in PLK1 promoter regulation (Zhu et al., 2002). Further investigations are 
needed in this regard to decide whether E2F binding sites are involved. 
Many G2/M genes have several CCAAT boxes. p53 can directly repress the 
promoters of those genes by forming a complex with NF-Y A and NF-Y C. 
PLK1, however, has only one CCAAT box (Imbriano et al., 2005). ChIP analysis 
could not detect p53 within the core promoter region containing the CAATT box 
of the PLK1 promoter (McKenzie et al., 2010). Consistent with that, Lin et al 
suggested a mechanism for regulation of CCAAT box containing promoters like 
PLK1 and CDC25A. They suggested that in unstressed cells CDK2 
phosphorylates nuclear factor YA (NF-YA) subunit of the CCAAT box which is 
responsible for sequence specific DNA binding. This association facilitates 
binding of NF-Y and CCAAT box and enables transactivation of PLK1 which is 
necessary for cell cycle progression. In stressed conditions on the other hand, 
p53 is activated which in turn induces p21. p21 then displaces CDK2 in 
interacting with NF-YA so there will be less association of CDK2 and NF-YA. 
This leads to CCAAT box-associated regulatory complex to have repressive 
function presumably by recruiting co repressors and HDACs (Lin et al., 2014) 


































Figure 3-1. Schematic representations of different mechanisms suggested for PLK1 repression by p53. 
Different mechanisms of repression of PLK1 by p53, proposed by different laboratories, are depicted. 
(A) In response to p53 activation, p53 binds to p53REs of PLK1 promoter and mediates its 
downregulation directly. (B) p53 induces its downstream target, p21, a CDK inhibitor. This blocks the 
CDK-mediated phosphorylation of RB-related pocket proteins (p107/130), keeping them in hypo-
phosphorylated state. As a result, p107/130 can join other proteins and form the inhibitory DREAM 
complex and subsequently PLK1 repression occurs. (C) p53 interacts with transcription factor E2F1 and 
forms an inhibitory p53–E2F1–DNA complex on the PLK1 promoter which results in suppression of E2F1 
mediated PLK1 expression. (D) p53 activation induces p21 which in turn inhibits CDK2-NF-Y interaction. 






The most recent of these proposed mechanisms (p53-p21-DREAM-CDE/CHR) 
may universally explain p53 mediated repression of a large set of genes 
including PLK1 (Fischer, Quaas, Steiner, et al. 2015). However, given that there 
are different (and apparently conflicting) mechanisms suggested by different 
groups and data from our own group showing that under certain circumstances 
PLK1 can still be repressed by p53 after elimination of p21, we were interested 
to further investigate this matter in greater depth.  
To resolve this issue, we either used Nutlin-3a or DNA damaging agents to 
induce p53. Nutlin-3a (hereafter Nutlin for simplicity) is a potent and selective 
small-molecule MDM2 antagonists. It binds to the p53 pocket of MDM2 and 
mimics the molecular interactions of 3 hydrophobic residues on p53 which are 
required for binding to MDM2. Thus, Nutlin works as a competitive inhibitor of 
the MDM2-p53 interaction and results in inhibition of p53 degradation by MDM2 
and ultimately p53 accumulation/stabilisation (Vassilev et al., 2004; Vassilev, 
2007). Etoposide and doxorubicin are topo-isomerase II inhibitors. Topo-
isomerase II is an enzyme that manages tangles and supercoils in the DNA by 
causing transient double strand breaks. After strand passage, topo-isomerase II 
relegates cleaved DNA (Hande, 2008). Etoposide and cisplatin inhibit this 
enzyme and cause double strand breaks (IR cause double strand breaks, too) 
(Santivasi and Xia, 2014). Cisplatin, and UV interfere with DNA replication by 
inducing DNA breaks which are effective blocks to RNA polymerase II (Mello, 
Lippard and Essigmann, 1995; Rastogi et al., 2010). The resulting DNA damage 
leads to activation of p53 pathway as discussed in section 1.3.3. The effect of 
p53 was then determined on the expression of either endogenous PLK1 levels 
or on a PLK1 promoter which had been fused upstream of the luciferase gene 




The aim of this chapter is to reassess mechanism(s) of repression of PLK1 by 





3.3.1 p53 induced by Nutlin causes repression of PLK1 
To estimate the effect of p53 on PLK1 repression, HCT116 (wild type, p53+/+) 
cells were treated with different p53 stabilising agents (these agents indeed 
increase the steady state levels of p53, but since they interfere with p53 
degradation by MDM2, they are referred to as p53 stabilising agents). Nutlin as 
explained before, is an inhibitor of MDM2 and stabilises p53 by preventing its 
degradation by MDM2 (Vassilev et al., 2004). Increasing concentrations of 
Nutlin cause a dose dependent stabilisation of p53 which is associated with 
reduction in PLK1 protein levels (Figure 3-2). These data suggest that p53 
could be involved in PLK1 downregulation as increasing concentrations of 
Nutlin causes decreasing levels of PLK1. Interestingly the MDM2 levels 
increases dramatically with Nulin treatment, however less increase in MDM2 
levels are observed when cells are treated with etoposide (whereas the p53 
levels goes up dramatically in both Nutlin and etoposide treatment). 
To further confirm that this effect is due to presence of p53, HCT116 p53-/- cells 
(an isogenic line which lacks full length p53) were treated with p53 stabilising 
agents. The data in Figure 3-2 clearly show that treatment of these cells with 
Nutlin does not change the PLK1 levels. On the other hand, looking back at the 
HCT116 p53+/+ results, treating the cells with DNA damaging agent etoposide, 
increases the levels of p53, but interestingly there seem to be no reduction in 
the PLK1 levels (Figure 3-2). 
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To minimize the chances that the phenomenon we observe is specific to one 
cell line only, similar experiments were performed with U2OS cells that have 
wild type p53. In U2OS cells, also, treatment with Nutlin increases the p53 
levels and downregulates PLK1 levels. However, p53 induced by etoposide and 
doxorubicin treatment resulted in a small reduction of PLK1 level and cisplatin 
and UV treatment did not cause any reduction in PLK1 (Figure 3-3 A). Similar 
to HCT116 p53-/- cells, silencing p53 in U2OS cells prevented the 
downregulation of PLK1 by p53 inducing agents (Figure 3-3 B).  
Looking back at the data in Figure 3-3 A, all the p53 stabilising agents seem to 
cause an increase in p21 levels, however there is no increase in p21 when cells 
treated with doxorubicin. It is particularly interesting because induction of p53 by 
doxorubicin is higher/equal to p53 induction by other DNA damaging agents 









Figure 3-2. p53 induced by Nutlin, but not etoposide, downregulates PLK1 in HCT116 p53+/+ cells. 
HCT116 cells were treated with increasing concentrations of Nutlin and etoposide for 24 hours. Cells 
were left untreated or treated with DMSO (vehicle) as control. Cell lysates were then used to perform 
western blot using antibodies indicated in the figure. HCT116 p53-/- cells were used as a control. These 





  Figure 3-3. Downregulation of PLK1 in U2OS cells in response to p53 induction by different agents.  
(A) U2OS cells were treated with increasing concentrations of Nutlin and DNA damaging agents for 24 
hours. (B) p53 was silenced (si p53) or mock silenced (NS) in U2OS cells followed by 24 hours treatment 
with different p53 stabilising agents. Untreated and/or DMSO (vehicle) treated cells were used as 
control. Cell lysates were then prepared to perform western blot using antibodies indicated in the 







3.3.2 Nutlin mainly induces G1 arrest whereas DNA damaging agents 
induce S or G2/M arrest 
We were then interested to see why there are differences between the 
responses seen by Nutlin and DNA damaging agents, and how such differences 
could be explained mechanistically. As PLK1 is a cell cycle dependent protein 
and its levels are regulated over the course of the cell cycle, the first question 
asked was whether different p53 stabilising agents lead to different cell cycle 
profiles and that could lead to the observed differences.  
Flow cytometry was carried out after labelling drug treated HCT 116 and U2OS 
cells with BrdU and propidium iodide. Analysis of the data showed that Nutlin 
mainly causes arrest in G1 whereas etoposide causes arrest predominantly in 
G2 phase. Cisplatin and doxorubicin on the other hand resulted in higher 
population of cells in S phase (Figure 3-4 A, B). Similar analysis in HCT116 
p53-/- cells were carried out. The data showed that these effects are mainly 
dependent on p53 as most of the cell cycle arrest disappeared in p53-/- cells 
(Figure 3-4 A). Therefore, one possible explanation for differences in PLK1 
levels after treatment with different p53 stabilising agents could be that different 
drugs cause arrest in different stages of the cell cycle and the levels of PLK1 
repression could be a reflection of the level of expression relative to its normal 
level at the given phase of the cell cycle.  
So, we proposed that Nutlin dissociates MDM2 and p53 interaction, as a result 
p53 gets stabilised and in turn induces p21 expression which mediates G1 
arrest, at which stage the levels of PLK1 are low. On the other hand, DNA 
damaging agents stabilise p53 after causing damage to DNA which then arrest 
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the cells in S or G2 phase, phases of the cell cycle in which PLK1 levels are 












Figure 3-4. Different p53 stabilizing agents result in different cell cycle profile.  
(A) HCT116 (B) U2OS cells were treated with Nutlin or DNA damaging agents (25 µM etoposide, 20 µM 
cisplatin, 100 nM doxorubicin) for 24 hours. Cells were then collected and labelled with propidium 
iodide and Brdu. Flow cytometry was carried out to estimate the population of cells in different phases 
of the cell cycle. Top panel are representative histograms and bottom panel is the quantification of the 












Figure 3-5. Schematic representation of proposed model for how Nutlin and DNA damaging agents 
might contribute to different behaviours in PLK1 repression by affecting cell cycle arrest.  
Nutlin causes p53 stabilisation by inhibiting p53-MDM2 interaction. As the result, p53 induces p21 
which is involved in G1 arrest, a stage of the cell cycle where PLK1 levels are low. DNA damaging 
agents, on the other hand, causes S and G2 arrest, where PLK1 levels are higher (the line graph is an 
estimation of PLK1 levels/activity and is not based on actual data). 
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3.3.3 Nutlin-induced accumulation of cells in G1 is p21 dependent and 
p21 knockdown can partly relieve the PLK1 downregulation 
As p21 is a classic downstream target of p53 which is involved in G1 arrest, we 
were interested to check if the G1 peak that appears in cell cycle analysis of 
cells treated with Nutlin (Figure 3-4) is due to induction of p21 by p53. To check 
this possibility p21 was silenced with p21 siRNA. Cell cycle analysis showed 
that when p21 is silenced, the G1 peak induced by Nutlin greatly reduces 
(Figure 3-6). So, the curious question then was what will happen at PLK1 levels 
in cells treated with Nutlin when p21 is silenced?  
To address this, p21 was silenced in the HCT116 and U2OS cells. The cells 
were then treated with Nutlin or DNA damaging agents. Western blot analysis 
showed that part of the PLK1 repression caused by induction of p53 is rescued 
in cells with silenced p21 compared to control cells expressing non-silencing 
siRNA (Figure 3-7 A, B). These data further support our hypothesis that p53 
mediated repression of PLK1 as determined/perceived from western blots could 
reflect cell cycle periodicity i.e. where in the cell cycle most of the population of 
the cells are at the time of analysing them. Also given the importance of p21 in 
PLK1 repression, as indicated by Figure 3-7 A, B, the data support the idea 
that the p21-DREAM-CDE/CHR model could be the major effector of PLK1 
repression by p53. Complete rescue of the PLK1 downregulation with p21 
siRNA is not observed either because p21 knockdown did not eliminate p21 
completely or because there might be additional/alternative mechanisms 
involved.  
To confirm the results of siRNA and eliminate the possibility that the residual 
p21 levels after p21 knockdown could have caused the small PLK1 repression, 
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we also used HCT116 p21-/- cells which are p21 null. Western blot analysis of 
HCT116 p21-/- cells showed that, similar to p21 knockdown results, 
downregulation of PLK1 in the Nutlin treated cells is still detectable (Figure 3-7 
C). However, since in HCT116 p21-/- cells treated with Nutlin the 
downregulation of PLK1 is very small as compared to HCT116 p53+/+ cells, it 
would have been helpful to quantify the data (by densitometry) to obtain the 




























Figure 3-6. p21 contributes to peak G1 population in cells treated with Nutlin.  
HCT 116 cells transfected either with NS siRNA or si p21 and then treated with 5 and 10 µM Nutlin or 25 
µM etoposide. Cells collected after 24 hours of treatment and labelled with propidium iodide and Brdu. 
Cell cycle analysis by flow cytometry carried out. (A) Histograms, (B) quantification of the results in A. 





 Figure 3-7. p21 knockdown can partly relieve the downregulation of PLK1 by p53. 
(A) HCT116 or (B) U2OS cells were transfected with si NS or si p21. Cells were then treated with 
different drugs for 24 hours after which lysates were prepared, and western blotting was carried out for 
various proteins indicated in the figure. (C) HCT 116 p53+/+ and its p21 null (p21-/-) and full length p53 
null (p53-/-) derivatives were treated with DMSO (vehicle, as control), Nutlin, etoposide or doxorubicin 
for 24 hours. Cells were then lysed and proceeded for western blotting with antibodies indicated in the 






3.3.4 The repression of PLK1 by p53 appears to occur by both p21 
dependent and p21 independent mechanisms 
To estimate the effect of p21 on PLK1 at the level of promoter activity, we used 
a pGL3 plasmid in which PLK1 promoter was fused upstream of luciferase 
gene, so luciferase could express under the control of PLK1 promoter. p21 was 
silenced in H1299 cells (which are p53 null) and PLK1 promoter activity was 
compared with control (mock silencing) after transfecting cells with p53. 
Luciferase reporter assays were performed and the results showed that there is 
a strong repression in PLK1 promoter activity upon p53 addition in both p21 
silenced cells and the control, however the reduction is less where p21 is 
silenced (Figure 3-8 A). These data suggest that p21 is important in PLK1 
repression by p53, but p53 can still repress PLK1 promoter in the absence of 
p21. 
Also, to further investigate how p21 and p53 can influence PLK1 promoter 
activity, H1299 cells ectopically expressing elevated p21 or p53 (along with 
PLK1 promoter fused to luciferase gene in a pGL3 plasmid) were analysed by 
luciferase reporter assay. The data suggest that p53 and p21 both cause 
reduction of PLK1 promoter activity. Cells in which both p21 and p53 were 
ectopically expressed, result in additive effect (Figure 3-8 B). These results 









Figure 3-8. p21 is important for p53 mediated PLK1 repression but it appears that a p21 
independent mechanism could be involved too. 
(A) H1299 cells were p21 silenced (si p21) or mock silenced (si NS) after which transfected with PLK1 
promoter along with either p53 or empty vector (E.V). Equal amounts of protein was used for each 
reaction. Luciferase assay was then carried out. (B) H1299 cells transfected with PLK1 promoter 
along with plasmids containing p53 (10 ng) or p21 (50 ng) or a combination of both plasmids. Empty 
vector (E.V) was used as a control. PLK1 promoter activity was then measured by luciferase assay 
(the experiment is normalised for protein not for transfection efficiency). The results are shown 
relative to empty vector (E.V). Western blotting was then performed with the samples from the 




3.3.5 Direct or indirect PLK1 repression by p53 could be cell line 
dependent 
As previously mentioned (section 1.2.5), PLK1 is a cell cycle dependent protein 
and its levels change as cells proceed through the cycle. This regulation is 
mediated by CDE/CHR elements in the promoter. With the data so far, we know 
that p21 could be important for p53 mediated repression of PLK1, but we don’t 
know whether this is simply through DREAM complex or other mechanisms 
could be involved too.  
To address this question, we first transiently transfected HCT116 p53+/+ and 
U2OS cells with plasmids containing PLK1 promoter (wild type or CDE/CHR 
mutated) fused to a firefly luciferase as a read out (see materials and methods 
Figure 2-1). An empty vector was used as a control. Transfected cells were 
then treated with Nutlin or etoposide to induce p53. Luciferase assays were 
performed to check the PLK1 promoter activity in these cells. Figure 3-9  shows 
that treatment with Nutlin caused repression of the wild type PLK1 promoter 
activity in both cell lines. Treatment with etoposide on the other hand showed 
apparent increase in HCT 116 and no/little (non-significant) changes in U2OS 
cells (similar to endogenous PLK1 protein levels showed in Figure 3-2 and 
Figure 3-3, suggesting that the reporter assays mirror physiological changes in 
PLK1 repression). Analysis of the CDE/CHR mutant PLK1 promoter showed 
loss of responsiveness in HCT 116 cells and partial loss in U2OS cells (Figure 
3-9). These data suggest that in HCT116 cells, CDE/CHR elements seem to 
play an important role in the repression mechanism, whereas U2OS cells seem 
to be able to still repress PLK1 promoter in absence of cell cycle regulatory 
element (CDE/CHR) but only in part.  
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Figure 3-9. Direct or indirect PLK1 repression by p53 could be cell line dependent.  
(A) HCT116 p53+/+, (B) U2OS cells transfected with empty vector (containing only the luciferase gene 
and not PLK1 promoter)/wild type PLK1 promoter/PLK1 promoter mutated at CDE/CHR element. 
Transfected cells were then treated with 10 µM Nutlin or 25 µM etoposide or DMSO (vehicle) as a 
control. After 24 hours of treatment samples were harvested and luciferase assay was carried out. These 
results are the average of 3 independent experiments. The numbers on the bars refer to p-value as 




We also used p53 null H1299 cells to further investigate the matter. Cells 
transfected with wild type and mutant PLK1 promoter plasmids and their 
performance were compared upon transfection with p53-expressing plasmid. 
Luciferase assay results showed that the repression of PLK1 promoter (both in 
wild type and CDE/CHR mutant) is stimulated by p53 in a dose-dependent 
manner. However, H1299 cells transfected with Wild type PLK1 promoter 
showed much sharper reduction of luciferase activity in response to p53 
compared to PLK1 promoter that has the CDE/CHR mutation (Figure 3-10). All 
together these data suggest a cell line dependency on CDE/CHR element in 






 Figure 3-10.  p53 induced PLK1 repression in H1299 cells partly depends on CDE/CHR elements.  
(A) H1299 cells transfected with either wild type or CDE/CHR mutated PLK1 promoter in combination 
with different amounts of p53 expressing plasmid. Empty vector (E.V, 0 ng of p53) was used as 
control. Luciferase assay was then carried out. (B) Western blot analysis was performed using the 
samples in figure A to check the transfection efficiency. These results are the average/representative 
of at least 2 independent experiments. 
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3.3.6 Cells stably transfected with PLK1 promoter mutated at CDE/CHR 
elements show constant expression of luciferase at different stages 
of the cell cycle 
To further confirm the data and eliminate any possible effect of transient 
transfection results might not be accurate, we generated the cells which stably 
express luciferase under control of PLK1 promoter (see section 2.4.9). By doing 
so we expect that cells harbouring plasmid containing wild type PLK1 promoter 
should express low luciferase levels/activity (which measures PLK1 promoter 
activity) at early stages of the cell cycle and increased/elevated expression at 
later stages (i.e., they should mirror endogenous PLK1 expression). Whereas 
expression of luciferase in cells with PLK1 promoter mutated at CDE/CHR 
elements is expected to be constant throughout the cell cycle. The effect of p53 
on expression of PLK1 in these cells (CDE/CHR mutant) then would be 
independent of CDE/CHR.   
To test this, cells were first synchronised by serum starvation for 24 hours. They 
were then collected after 0, 4, 12, 16 and 24 hours following replacement of 
serum free media with media containing 10% FBS. Luciferase reporter assay 
was then carried out. Figure 3-11 A shows that after re-treating the cells with 
media containing serum, which should allow the cells to re-enter cell cycle and 
progress synchronously, PLK1 promoter activity increases over time in clones 
with wild type PLK1 promoter. Whereas in clones with PLK1 promoter mutated 
at CDE/CHR elements constant PLK1 promoter activity is observed in different 
time points. Western blot analysis also confirmed that Luciferase levels increase 
over time only in cells having wild type PLK1 promoter and not in PLK1 
promoter with CDE/CHR mutation. Endogenous PLK1 levels however increase 
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in both cell lines containing wild type and mutated PLK1 promoter (Figure 3-11 
B).   
Here it would have been helpful to confirm the cell cycle profile of our samples 
at different time points collected. Cell cycle analysis by flow cytometry or even 
western blot analysis using antibodies against Rb or different cyclins would help 
us to determine whether cells have remained synchronised after re-stimulation 






Figure 3-11. Cells stably transfected with PLK1 promoter mutated at CDE/CHR elements show 
constant expression of luciferase at different stages of the cell cycle.  
(A) U2OS cells stably express wild type PLK1 promoter/PLK1 promoter mutated at CDE/CHR 
elements/empty vector (use as control) fused to a luciferase reporter gene were synchronised by serum 
starvation for 24 hours. Lysates of cells collected at different time points after terminating serum 
starvation. Luciferase assays were then performed to measure PLK1 promoter activity. (B) Western blot 
analysis performed by using the samples used in luciferase assay, for the proteins indicated in the figure. 
These results are representative of 2 independent experiments. 
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3.3.7 PLK1 repression by Nutlin in U2OS cells is only partly dependent 
on CDE/CHR elements 
Next, we treated the aforementioned stable cell lines with p53 stabilising agents 
and checked the PLK1 promoter activity. In the cells that have the wild type 
PLK1 promoter, the repression of PLK1 promoter occurs upon treatment with 
Nutlin, etoposide and doxorubicin. Interestingly, the repression occurs with all 3 
agents even in cells harbouring mutation in the CDE/CHR element (Figure 
3-12). These data demonstrate that in these cells p53 mediated repression of 
PLK1 could still happen without the functional CDE/CHR elements. Figure 3-13 
A and B shows the results of two independent clones. 
To confirm that the effect we observe is indeed due to p53, we silenced p53 by 
siRNA in the clones and then treated the cells with p53 stabilising agents. In 
cells harbouring wild type PLK1 promoter, treating the cells with all 3 agents 
caused repression of the PLK1 promoter when p53 was present, however in the 
p53 silenced cells, the repression was relieved, suggesting that p53 indeed is 
necessary for the repression mechanism. On the other hand, in cells harbouring 
mutated CDE/CHR element, the repression occurs in the control cells (non-
silencing siRNA) upon treatment with all 3 agents, however silencing p53 
completely abolishes the PLK1 repression by Nutlin only, the repression by 





Figure 3-12. PLK1 repression by p53 seems to be independent of CDE/CHR and cell cycle regulation in 
U2OS cells.  
U2OS cells stably express wild type PLK1 promoter/PLK1 promoter mutated at CDE/CHR 
elements/empty vector were treated with DMSO (as vehicle control), 10 µM Nutlin, 25 µM etoposide or 
100 nM doxorubicin for 24 hours. Samples were then lysed and proceeded for luciferase assay analysis. 





Figure 3-13. p53 dependency of PLK1 repression induced by different p53 inducing agents. 
(A) U2OS stable lines were transfected with si p53 or si NS (as control) and then treated with 10 µM 
Nutlin, 25 µM etoposide or 100 nM doxorubicin. DMSO (vehicle) treated cells were used as control. 
Luciferase assay was then performed. (B) Western blot analysis were carried out with the luciferase 
assay samples in figure A to check the knock down efficiency. These results are representative of 2 
independent experiments.     
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3.3.8 The repression of PLK1 by p53 may be more complex than 
regulation through the CDE/CHR elements alone 
As there are conflicting results published in the literature regarding which part of 
PLK1 promoter is required for its repression through p53, we wanted to see 
what will happen if we have deletions of the p53REs and mutation of CDE/CHR 
elements together; would p53 still cause repression of PLK1 promoter? 
Plasmids containing wild type PLK1 promoter, PLK1 promoter that has deletion 
in p53RE1, or deletions of both p53RE1 and p53RE2 upstream of luciferase 
gene in pGL3 plasmid (previously made in the laboratory, (Iyer et al., 2014)) 
were used to introduce CDE/CHR mutations.  
We used HCT116 p53+/+ and U2OS cells, transfected them with the above 
plasmids and then treated them with Nutlin to induce p53. Luciferase assays 
were then carried out. Figure 3-14 A shows that in HCT116 cells, there is PLK1 
repression upon Nutlin treatment with or without p53RE deletions, however this 
repression is not seen when CDE/CHR is mutated, further confirming the 
previous data that the PLK1 repression by p53 in these cells is dependent on 
CDE/CHR elements.  
Similarly, in U2OS cells there was very little difference in luciferase expression 
in wild type and p53REs deleted plasmid transfections. Also, mutation of the 
CDE/CHR elements had only minimal effect on relieving the repression (Figure 
3-14 B), further confirming that in U2OS cells the repression of PLK1 by p53 is 




We also used p53 null H1299 cells and transfected them with the different 
truncated and mutated PLK1 promoter plasmids along with increasing levels of 
p53. Luciferase assay analysis showed that p53 causes repression of wild type 
PLK1 promoter, but part of this repression is lost when CDE/CHR is mutated. 
Deletion of p53RE1 or p53RE1+2 has no/minimal effect on the repression. 
Similarly, when both CDE/CHR elements and the p53REs were mutated there 









Figure 3-14. p53 responsive elements of PLK1 promoter seem to have no significant role in PLK1 
repression by p53.  
(A) HCT116 (B) U2OS cells were transfected with WT and different mutated versions of PLK1 
promoter (as labelled in the figure). Transfected cells were then treated with Nutlin or DMSO (vehicle 
control) for 24 hours after which cells were lysed and luciferase assay was performed. These results 




  Figure 3-15. p53 dependent repression of PLK1 occurs even in absence of p53REs and 
functional CDE/CHR elements.  
(A) H1299 cells were transfected with WT and different mutated versions of PLK1 promoter (as 
labelled in the figure). Different amounts of p53 expressing plasmid were co-transfected. Cells 
were lysed, and luciferase assay was performed. (B) Western blot analysis of the samples used 





3.3.9 Phosphorylation of p53 at serine 15 is involved in PLK1 repression 
It has been previously shown that phosphorylation of p53 at serine 15 is critical 
for stimulating the transactivation of genes (Loughery et al., 2014). We were 
curious to see whether the same is true in p53 mediated repression of PLK1.  
p53 null H1299 cells were used and transfected with PLK1 promoter plasmid 
and increasing levels of plasmids expressing either wild type p53 or p53 that 
has the serine 15 substituted by alanine (S15A, to prevent phosphorylation) or 
aspartic acid (S15D, phosphomimic). Empty vector was used as control. 
Luciferase assay analysis showed that part of the reduction of PLK1 promoter 
activity, caused by wild type p53, is lost with S15A mutant. Also, using a 
phosphomimic mutant (S15D) enhanced the repression of PLK1 promoter 
(Figure 3-16 A).  
Looking closely at the western blot results (Figure 3-16 B), p21 levels are 
higher in S15A mutant compared to wild type p53 which is difficult to explain 
knowing that serine 15 phosphorylation is required for transactivation of p21 as 
reported by Loughery et al. (2014). Having a blot for p53 (pS15) would have let 
us to interpret the data better. Also, it would have been nice to have another 
control (for example a blot for MDM2) or even a luciferase assay for p21 












Figure 3-16. Phosphorylated p53 at serine 15 is partly required for p53 mediated PLK1 repression.  
(A) H1299 cells transfected with plasmid containing wild type PLK1 promoter in combination with 
different amounts of plasmids expressing wild type p53, p53 (S15A) or p53 (S15D). Empty vector 
(E.V) transfected cells were used as control. Luciferase assay was then performed. (B) Samples of the 
luciferase assay were used for western blotting to check the transfection efficiency. These results are 





3.3.10 p53 requires an intact N-terminus and DNA binding domain to 
repress PLK1 
Since many of the domains of p53 are required for its activity (as explained in 
section 1.3.1), we were interested to see which part of p53 molecule is 
responsible for the repression of PLK1. A number of plasmids were used each 
containing mutation(s) in p53 gene (Figure 3-17) and measured against the 
performance of wild type p53. One of the plasmids contained two mutations 
(L22Q/W23S) in transactivation domain 1, TAD1, which binds to the co-activator 
p300; (these mutations correspond p53 residues 25 and 26 in murine cells and 
are required for p53 dependent transcription of genes (Hammond et al., 2006). 
Another plasmid we used had the proline rich domain deleted (∆Pro.). Two 
other plasmids were used that had mutations in the DNA binding domain and 
are believed to cause gain of oncogenic functions; R175H causes a 
conformational change in the site-specific DNA binding domain so makes it 
unable to bind to the DNA. R273H does not cause a conformational change but 
eliminates a residue that is important for DNA contact (Muller and Vousden, 
2013) (Figure 3-17). 
p53 null H1299 cells were transfected with PLK1 promoter along with increasing 
amounts of wild type or mutated p53 plasmids. Luciferase assay results for 
plasmids having mutations in N-terminus of p53 (L22Q/W23S and ∆Pro) 
showed that PLK1 promoter represses with wild type p53 (more repression in 
wild type PLK1 promoter compared to CDE/CHR mutant), whereas none of the 
mutants of p53 could cause repression of either wild type or CDE/CHR mutated 
PLK1 promoter (Figure 3-18 A, B). The response of empty vector to different 
amounts of p53 expressing plasmids was checked as control.  
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The response of PLK1 promoter to p53 expressing plasmids that has mutations 
in DNA binding domain was similar to the N-terminus mutated p53; where wild 
type p53 could repress the PLK1 promoter, there was no repression seen by 






















Figure 3-18. Repression of PLK1 by p53 requires an intact N-terminus of p53.  
H1299 cells were transfected with PLK1 promoter (WT or CDE/CHR mut.) or empty vector as control. 
Different amounts of WT or mutated ((A) L22Q/W23S, (B) ∆ Pro.) p53 expressing plasmids were 
transfected as well, empty vector (E.V, 0 ng of p53) was transfected as control. Cells were then lysed 
and proceeded for Luciferase assay and western blot analysis. Because of the differences in 
luciferase expressions of each plasmid, it was very difficult to compare if we normalised the values to 
the 0 ng of E.V. So, the luciferase results have been normalised to the 0 ng of p53 for each E.V, WT or 







Figure 3-19. Repression of PLK1 by p53 requires an intact DNA binding domain of p53.  
H1299 cells were transfected with PLK1 promoter along with different amounts of WT or mutated 
((A) R175H, (B) R273H) p53 expressing. Empty vector (E.V, 0 ng of p53) was transfected as control. 
Cells were then lysed and proceeded for Luciferase assay and western blot analysis. These results are 




In this chapter, we have confirmed that p53 can cause downregulation of PLK1 
in response to Nutlin, a pharmacological inhibitor of MDM2. This downregulation 
is dose dependent and is absent in cells that lack full length p53 or in cells in 
which p53 expression has been silenced. Surprisingly, DNA damaging agents 
caused induction of p53 but the effect on PLK1 levels varied between the 
different agents used. As all of these agents (Nutlin and DNA damaging agents) 
stabilise p53, and given that p53 clearly represses PLK1 (McKenzie et al., 2010; 
Fischer, Quaas, Nickel, et al., 2015; Lin et al., 2014), we were very curious to 
understand why these different agents give rise to apparently different 
responses. Here using a more quantifiable method would have been helpful (for 
example using densitometry for western blots) to identify the fold decrease in 
protein levels.  
The results of the cell cycle analysis are particularly interesting as they suggest 
that different p53 stabilising agents arrest the cells in different phases of the cell 
cycle. This led us to the hypothesis that the apparent PLK1 downregulation by 
p53 (as determined by measuring PLK1 levels by western blots) could reflect 
the PLK1 levels at the point of the cell cycle at which the arrest occurs. Thus if 
an agent results in an enriched population of cells in a phase of the cell cycle 
where PLK1 levels are low, we observe an apparently higher downregulation 
and vice versa (Figure 3-5).                                                                                                                                                                                                                                                                                                                                                                                                                                                               
This hypothesis was examined by silencing p21, classic downstream target of 
p53 which is involved in cell cycle arrest particularly in G1 phase. Cell cycle 
analysis showed that p21 is responsible for the predominantly G1 arrest in the 
Nutlin treated cells. Knowing that Nutlin treatment on p21 silenced cells reduces 
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G1 population (a phase of the cell cycle where PLK1 levels are low), western 
blotting was carried out to check the levels of PLK1 in absence of p21. The data 
indicate that repression of PLK1 by p53 is partly p21 dependent and p53 can 
still repress the PLK1 promoter in absence of p21, as the PLK1 repression by 
p53 is not suppressed completely in Si p21 treated cells. However, one might 
argue that p21 knockdown might not be efficient enough and the small residual 
p21 levels could be enough to repress PLK1. So, the HCT116 p21-/- cells were 
used. Also, the role of p21 in p53 mediated repression of the PLK1 promoter 
was investigated and similar conclusions were drawn (partial involvement of 
p21).  p21 independent repression of PLK1 by p53 has been reported 
previously by our laboratory (McKenzie et al., 2010).  
These findings raised the question of whether p53 represses the PLK1 
promoter directly or through DREAM interacting with cell cycle dependent 
elements (CDE/CHR) or through other mechanisms. This made the basis of our 
investigations regarding p53 mediated PLK1 repression mechanism. We used a 
system in which the PLK1 promoter (wild type or CDE/CHR mutant) cloned in a 
reporter vector, was used as a readout for PLK1 promoter activity. Our data 
showed a cell line dependency and suggested that different cell lines may vary 
the mechanisms they use to downregulate PLK1 by p53. The data from the 
experiments using the HCT116 cells show that PLK1 repression are largely or 
even completely dependent on the presence of an intact CDE/CHR element 
(Figure 3-9 A), and therefore agree with the DREAM complex model proposed 
by Fischer et al. (2015). On the other hand, the data from the experiments using 
the U2OS cells (Figure 3-9 B) showed that following mutation of the CDE/CHR 
elements, there remains a significant level of p53-dependent PLK1 repression. 
This repression was not dependent on p53REs either (Figure 3-14). 
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Furthermore, the data from the experiment by which p53 were ectopically 
expressed in p53 null H1299 cells (Figure 3-10), indicate partial involvement of 
CDE/CHR elements in PLK1 repression. These data suggest therefore that, 
while DREAM complex acting via the CDE/CHR elements may provide a level 
of repression in the U2OS and H1299 cells, there is another mechanism(s) in 
these cells that represses PLK1 independently of CDE/CHR.  
 
Overall the mechanism of PLK1 repression by p53 seems to be complex as the 
data published in the literature look conflicting and varies between different 
studies. In the interest of time, our focus in this chapter was mainly on p53-
p53REs and p53-p21-DREAM-CDE/CHR mechanisms. Further investigations 
are required to fully understand the mechanism(s) by which p53 represses 
PLK1 and what is responsible for choosing different mechanisms by different 
cell lines.  
Altogether, the conflicting data in the literature regarding the mechanism of 
PLK1 repression by p53, could indicate that there might be several pathways 
involved. Involvement of more than one pathway in p53-mediated repression, 
has also been reported in other genes, too. Investigations of p53 mediated 
repression of CDC25C using luciferase reporter assay by Clair et al. showed 
that p53 downregulates CDC25C by two different mechanisms. One of the 
mechanisms is direct binding of p53 to the p53 binding sites. The second 
mechanism is through CDE/CHR elements and was found to be independent of 
p21, as p53 could still repress the promoter in the HCT116 p21 null cells. 
However, p21 alone could repress the expression of the reporter gene, this 
repression abolished in CDE/CHR mutated promoter. The authors proposed 
that repression of CDC25C by p53 through CDE/CHR elements could occur via 
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both p21 dependent and p21 independent mechanisms (Clair et al., 2004). 
CDC25C has also been reported by an independent study to be repressed by 
direct interaction of p53 to the CCAAT boxes (Imbriano et al., 2005).  
Since p53 gets stabilised by post translational modifications, it would be 
interesting to know which post-translational modifications are involved in the 
repression of PLK1 by p53. We have shown that phosphorylation of p53 at 
serine 15 is involved in PLK1 downregulation. As it has been published before, 
serine 15 phosphorylation is necessary for p53 mediated transactivation of 
genes (Loughery et al., 2014). Hence, Involvement of p53 phosphorylation at 
serine 15 in PLK1 repression, fits with a p53 transactivation-based mechanism 
(as do the results with p53 mutants). However, it does not make it clear whether 
p53 phosphorylation at serine 15 is required for direct p53 repressive function 
too, or it is required simply for transactivation of genes that can repress PLK1 
(an indirect regulation). A similar experiment but with CDE/CHR mutated PLK1 
promoter would help to eliminate the possibility that introducing each of these 
p53 expressing plasmids to the cells might result in different cell cycle profile 
and hence the PLK1 promoter activity relevant to that particular point of the cell 
cycle.  
Overall the findings of this chapter show that PLK1 repression by p53 through 
CDE/CHR elements or by other mechanisms appear to be cell line dependent 
and there might be more than one pathway involved. However, the complete 





Chapter 4: PLK1 Inhibition-Induced Mitotic Arrest 
and DNA Damage Response Differs 





4.1.1 Cell division cycle and checkpoints 
The cell division cycle (also called cell cycle for simplicity) is the process by 
which all living cells replicate and divide by an orderly sequence of events to 
produce two identical daughter cells. In eukaryotic cells the cell cycle is divided 
into two major phases: Interphase and mitotic (M) phase. Interphase takes 
about 95% of the cell cycle (time wise) and can be subdivided into 3 parts; G1 
in which cells undergo growth and normal metabolic roles, S phase is DNA 
replication phase and G2 is the stage when cells grow and prepare to undergo 
mitosis (Diaz-Moralli et al., 2013). M phase lasts just about 5% of the cycle 
(Heijink, Krajewska and Van Vugt, 2013) and can be subdivided into mitosis 
and cytokinesis which are responsible for nucleic and cytoplasmic divisions 
respectively. 
The cell cycle is controlled by a complex network of regulatory proteins called 
checkpoints. These are mechanisms that can prevent progression to the next 
stage of the cell cycle, if impairment have been detected (Kastan and Bartek, 
2004). The most prominent checkpoints in eukaryotic cells are located at the 
boundary of G1 and S phase, at the G2/M transition and between metaphase 
and anaphase of mitosis. These checkpoints together with associated 
regulatory proteins such as cyclins and cyclin dependent kinases (CDKs) work 
toward an error free cell division. Without these control mechanisms, aberrant 
cell division and genomic instability could occur leading to cancer (Wenzel and 




Mitosis itself can be subdivided into 5 stages namely prophase, prometaphase, 
metaphase, anaphase, and telophase. During this phase of the cell cycle, 
chromosomes undergo dynamic changes in their morphology and movement 
(Pines and Rieder, 2001).  
Mitosis starts when replicated interphase chromosomes become visible in 
prophase. Kinetochores assemble on the chromosome centromere at the same 
time. Nuclear envelop breakdown is the hallmark of prophase termination and 
initiation of prometaphase. In prometaphase, spindle microtubules attach to 
kinetochores (Cheeseman and Desai, 2008). In order to ensure the fidelity of 
sister chromatid separation, the mitotic checkpoint/spindle assembly checkpoint 
(SAC), monitors the progression of mitosis and remains active until metaphase. 
In case of any defects in kinetochore-spindle microtubule attachments, SAC 
senses it and prevents the progression to the next stage until all chromosomes 
attach correctly to the microtubule spindle (Acquaviva and Pines, 2006). By 
metaphase, all sister chromatid pairs are aligned in the equator of the cell 
with all kinetochores correctly attached to the microtubule spindles 
(Cheeseman and Desai, 2008). Upon satisfaction of SAC, Anaphase 
promoting complex/cyclosome (APC/C), an E3 ubiquitin ligase, is activated 
and targets its substrates for degradation (Cheeseman and Desai, 2008; 
Musacchio and Salmon, 2007). In anaphase, sister chromatids move away 
from each other by the force of microtubules. Splitted sister chromatids start 
decondensing by the onset of telophase. Subsequently the nuclear envelop 
re-forms to generate the nuclei of daughter cells which is then followed by 
cytokinesis (Hayashi and Karlseder, 2013).  
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4.1.3 Importance of mitosis  
About 100 million cells in every human body undergo mitosis every minute. 
Mitosis is the shortest phase of the cell cycle, but it has an important role in the 
accomplishment of cell division. The chromosomes that have been replicated in 
S phase, separate in mitosis and genetic information transfers to daughter cells 
(O’Connor, 2008; Ganem and Pellman, 2012). 
Cells going through mitosis undergo lots of stresses; Nuclear envelop break-
down, reorganisation of Golgi and endoplasmic reticulum membrane system, 
chromosome condensation, changes in the shape of actin and microtubules, 
cessation of vesicle trafficking, disabled transcription and slowed translation are 
hallmarks of mitosis (Ganem and Pellman, 2012). Because of these dramatic 
perturbations to the normal architecture of the cells, mitosis is believed to be the 
most fragile phase in the cell cycle and activation of apoptosis in response to 
insults is very common during this period (Chan, Koh and Li, 2012).  
As mentioned in the last section, in cells undergoing mitosis the SAC is active 
until all kinetochores attach properly to the spindle microtubules. Any insult that 
prevents such correct attachment results in prolonged maintenance of the SAC 
and causes cells to arrest in mitosis until the damage is repaired and all 
kinetochores attach correctly, or else cells might undergo mitotic cell death 
(Musacchio and Salmon, 2007). This is one of the anti-proliferative mechanisms 
induced by chemotherapeutic agents (Chan, Koh and Li, 2012)                                                                                                                                                                                                                          
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4.1.4 Mitotic arrest and DNA damage: 
As discussed, Mitotic cells experience lots of stresses explaining why mitosis 
needs to be a short period. Prolonging the period of mitosis leads to a stress 
response in cells and could cause chromosome breaks/DNA damage (Orth et 
al., 2012; Dalton et al., 2007; Ganem and Pellman, 2012) which can ultimately 
lead to inhibition of cell proliferation or induction of apoptosis. These outcomes, 
in fact, can block the proliferation of cells with aberrant chromosomes and can 
inhibit genomic instability. This mechanism is important for the effectiveness of 
the anti-mitotic drugs against cancer cells (Hain et al., 2016).  
The reasons for DNA damage induced after prolonged mitosis are still under 
investigations but Orth et al.  demonstrated that it could be because of outer 
mitochondrial membrane permeabilisation after the long mitotic arrest which 
leads to cytochrome c leakage. They concluded that the DNA damage caused 
by prolonged mitotic arrest is caspase dependent as the damage was inhibited 
when caspase inhibitors were used (Orth et al., 2012). Hayashi and colleagues 
used the method of γ-H2AX staining as a marker to detect DNA damage and 
telomere fluorescence in situ hybridisation (FISH) technique to detect the 
telomeres (sequence of repetitive nucleotides at the end of the chromosomes). 
The co-localisation of γ-H2AX foci and telomeres, which indicates the telomeric 
damage, was found in cells undergoing prolonged mitosis (Hayashi et al., 
2012). 
Eukaryotic cells have evolved a complex of proteins located at the end of 
telomeres, termed shelterin. The shelterin complex is composed of double 
stranded repetitive sequence of 5’-TTAGGG-3’ (with the complementary DNA 
strand being 3’-AATCCC-5’) followed by a single stranded G-rich 3’ overhang 
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which is associated with the complex of 6 proteins. Shelterin functions to cap 
and protect chromosome ends, and enables the cells to differentiate between 
chromosome ends and DNA breaks (de Lange, 2009; Palm and de Lange, 
2008).  
The 6 subunits of shelterin complex are TRF1, TRF2, POT1, TIN2, Rap1 and 
TPP1. Among the subunits, TRF2 and POT1 have been reported to be more 
predominantly involved in chromosome end protection by repressing the ATM 
and ATR DNA damage signalling pathways and consequent checkpoint 
activation (Denchi and de Lange, 2007). It has been suggested that during 
mitotic arrest TRF2 is partially removed from telomeres, causing partial 
telomere deprotection/dysfunction of telomeres and subsequent DNA damage 
response at the end of chromosomes (Hayashi et al., 2012). 
4.1.5 Targeting mitosis for cancer therapy: 
One of the clinically effective approaches which is widely used in cancer 
therapy is to disrupt mitotic progression (Driscoll et al., 2014). These agents 
interfere with normal mitotic progression but are ineffective against non-dividing 
cells (Chan, Koh and Li, 2012).  Microtubule poisons such as nocodazole and 
colchicine are among the first studied agents causing mitotic arrest and 
consequent DNA damage. These agents bind β-tubulin and act on the 
polymerisation dynamics of microtubule spindles which is crucial for their proper 
function (Mukhtar et al., 2014). Therefore, they maintain the activity of the SAC 
by preventing kinetochore attachment. The resulting prolonged mitotic arrest 
that occurs ultimately causes cells to undergo cell death or slip out of mitosis 
without completion of anaphase or cytokinesis (Ganem and Pellman, 2012).  
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Although microtubule poisons are very effective and widely used in cancer 
therapy, the side effects associated with them are very common and severe. 
They are meant to selectively affect the cells in mitosis only, but the possibility 
that they affect interphase cells too, is very high as microtubules are 
widespread during the whole process of the cell cycle. Therefore, they can have 
unwanted effects on non-proliferating cells. On the other hand, complications 
related to resistance to these agents is not uncommon (mainly due to drug 
efflux pumps or mutations in tubulin). So the attention has been towards finding 
novel drugs that still target the mitotic progression but with a different 
mechanism of action compared to microtubule poisons, of such agents are 
kinase inhibitors (Chan, Koh and Li, 2012; Matson and Stukenberg, 2011).  
The evolutionary conserved regulatory function of cyclin dependent kinases 
(CDKs) opened new avenues to understand the mitotic progression and 
stimulated a search for other kinases which work together with CDKs to 
regulate cell division. PLKs are one of the most prominent families of these 
kinase proteins that as highlighted in Figure 1-2 have critical functions 
throughout mitosis (Barr, Silljé and Nigg, 2004).  
Scientists studying mitotic arrest, most commonly use microtubule poisons to 
study the consequences of prolonged mitotic arrest. We were interested in 
focusing on PLK1 and how inhibitors of PLK1 affect mitosis, and what outcome 
such inhibition might bring about especially in terms of DNA damage. Immuno-
fluorescence studies were carried out in most of the experiments in this chapter 




The Aim of this chapter is to determine whether inhibition of PLK1 induces a 
DNA damage response in mitosis similar to that induced by microtubule poisons 





4.3.1 Inhibition of PLK1 causes the formation of mono-polar spindles 
As discussed before (see section 1.2.2), PLK1 has important roles in maturation 
and separation of centrosomes and assembly of bipolar spindles mainly by 
recruiting γ-tubulin. Inhibiting PLK1 is expected to disturb the assembly of 
bipolar spindles as it interferes with the separation of centrosomes. This 
concept was investigated by treating the cells with the PLK1 small molecule 
inhibitor, BI2536. A549 and U2OS cells were treated with BI2536 for 2 hours, 
after which mitotic wash off was carried out. Collected mitotic cells re-pated in 
the media containing BI2536 for further 2 (A549) or 4 (U2OS) hours. Cells were 
then fixed and stained with α-tubulin antibody and immuno-fluorescence was 
carried out. In a similar approach, cells were treated with microtubule de-
polymeriser, nocodazole and immuno-stained with α-tubulin antibody. Normal 
mitotic cells were used as control. Figure 4-1 shows a representation of the 
images taken. In normal mitosis we see proper bipolar spindle formation where 
the cells will divide normally. In the nocodazole treatment, microtubules had not 
polymerized so the microtubules cannot attach to kinetochores and in BI2536 
treated cells we see the formation of monopolar spindles.  
Interestingly, looking at the nocodazole treatment in A549 (Figure 4-1 A) and 
U2OS cells (Figure 4-1 B), there seems to be a different morphology of 
microtubules between the 2 cell lines. In other words, it appears that A549 cells 
are more sensitive to microtubule de-polymerisation effect of nocodazole as 




Figure 4-1. Morphology of microtubules of the cells treated with different mitotic poisons.  
(A) A549 (B) U2OS cells were treated with nocodazole/BI2536 for 2 hours, mitotic wash off was then 
carried out. Collected mitotic cells were left for another 2/4 hours (A549/U2OS respectively) in 
media containing drug before cells undergo immuno-staining. Normal mitotic cells were used as 
control. Representive images are shown. 
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4.3.2 Inhibition of PLK1 arrests the cells in mitosis 
As mentioned in the introduction chapter, in prometaphase and metaphase 
PLK1 localizes to the kinetochores and spindle poles to regulate assembly of 
the kinetochores and contributes to the spindle assembly checkpoint 
(Degenhardt and Lampkin, 2010). When PLK1 is not present, bipolar spindles 
do not form and thus cells arrest in prometaphase as a result of checkpoint 
activation (Barr, Silljé and Nigg, 2004). We therefore decided to use a range of 
concentrations of the PLK1 inhibitor BI 2536 to see the response of the cells to 
different concentrations at different time points in terms of mitotic arrest. Initially 
U2OS cells were treated with BI2536 for 2 hours. Then the floating, mitotic cells 
were collected and re-plated into BI2536 containing media for further 2 or 4 
hours (P4M and P6M respectively).  
Washing off mitotic cells and re-plating them for further 2 or 4 hours in BI2536 
containing media enabled us to see if cells would still be in mitosis after that 
length of time (2/4 hours). Because if PLK1 does not arrest the cells in mitosis, 
after 2/4 hours, cells should have exited mitosis. Cells were then collected, 
cytospun and stained with an antibody against histone H3 phosphorylated at 
serine 10, a commonly used marker of mitotic cells. Confocal microscopy was 
then used to analyse the stained cells. Analysis of the images showed that 
BI2536 causes mitotic arrest even in the lowest concentration used (10 nM) 












Figure 4-2. PLK1 inhibition results in mitotic arrest.  
U2OS cells were treated with different concentrations of BI2536 for 2 hours followed by mitotic 
wash off and re-plating the mitotic cells in the same media containing BI2536 for another 2 or 4 
hours (P4M/P6M). Cells were then collected, cytospun and stained with anti-phospho Ser10-histone 





4.3.3 BI 2536 causes a time and dose dependent DNA damage 
Prolonging the period of mitosis, by using microtubule poisons, has been 
documented to induces DNA damage (Colin et al., 2015; Dalton et al. 2007). 
We were interested to check whether this was also the case when cells were 
arrested in mitosis using the PLK1 inhibitor. Cells were treated with different 
concentrations of BI2536 and after 2 hours floating mitotic cells were collected 
and re-plated in BI2536 containing media for further 2 or 4 hours. Normal mitotic 
cells and nocodazole-treated cells were used as controls. Immuno-staining 
performed using an antibody against γ-H2AX (pS139), a marker of DNA 
damage. Analysis of the results, by counting γ-H2AX foci in mitotic cells, 
showed that PLK1 inhibition causes a dose-dependent DNA damage response 
(DDR), which further increases over time (Figure 4-3). In other words, the 
intensity of the DNA damage signalling observed after treating the cells with 
PLK1 inhibitor is under the influence of both concentration of BI2536 and the 





Figure 4-3. Time and dose dependency of BI2536-induced DNA damage response.  
(A) U2OS cells were treated with 100ng/ml of nocodazole or different concentrations of BI2536 for 2 
hours followed by mitotic wash off and re-plating the mitotic cells in the same media containing 
BI2536 for another 2 or 4 hours. Normal mitotic cells (Untreated mitotic cells) were used as control. 
Cells were then collected, cytospun and immuno-stained using anti-phospho-Ser10 histone H3 and 
anti-γH2AX antibody. (B) Representative images of normal mitotic cells, nocodazole/BI2536 treated 
cells for 2 hours followed by mitotic wash off and incubation for another 4 hours in the same media 




4.3.4 Inhibition of PLK1 results in both telomeric and non-telomeric 
damage and partial dissociation of TRF2 from telomers 
Cells have evolved a sequence of repetitive nucleotides at the end of the 
chromosomes called telomeres. These structures function to prevent the 
chromosome ends being recognised as sites of DNA damage and thereby 
prevent activation of checkpoint and cellular DNA damage response which 
could lead to cell cycle arrest and DNA repair activation that may cause 
disastrous consequences for genome integrity (de Lange, 2009). 
 
Previous work from our laboratory has shown that most of the DNA damage 
caused by microtubule poisons is localised at the telomeres (Hain et al., 2016). 
We were interested to know whether this is also the case when cells are treated 
with the PLK1 inhibitor. To test this, we stained the treated cells with an 
antibody against γ-H2AX to detect DNA damage followed by Fluorescence In 
Situ Hybridisation (FISH) with a telomere specific probe to visualise telomeres. 
Co-localisation of γ-H2AX foci and telomeres indicates telomeric DNA damage, 
the so-called telomere dysfunction induced foci (TIFs). In contrast to the DNA 
damage caused by microtubule poisons, which is mostly telomeric, there seems 
to be no obvious difference between the number of telomeric and non-telomeric 
DNA breaks in PLK1 inhibitor treated cells (Figure 4-4 A, B). 
As mentioned in section 4.1.4, eukaryotic cells have evolved a complex of 
proteins at the end of their telomeres, called shelterin, that functions to cap and 
protect chromosome ends, and enables the cells to differentiate between 
chromosome ends and DNA breaks (de Lange, 2009; Palm and de Lange, 
2008). Extensive works from our laboratory and another laboratory suggested 
that during mitotic arrest TRF2 (a subunit of shelterin) is partially removed from 
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telomeres causing partial telomere deprotection and subsequent DNA damage 
(Hayashi et al., 2012; Hain et al., 2016). Since the proportion of telomeric to 
non-telomeric DNA damage induced by nocodazole and BI2536 is different, the 
curious question was then whether PLK1 inhibitors behave the same as 
microtubule poisons in causing to displace TRF2 from the telomeres? To 
investigate this, mitotic cells from nocodazole or BI2536 treated cells were 
stained for TRF2 and number of TRF2 foci in each mitotic cell was counted. 
Cells treated with nocodazole and BI2536, both caused loss of TRF2 from 
telomeres, with nocodazole causing more TRF2 loss compared to BI2536 
(Figure 4-5). There are no error bars on the bar graph since the experiment has 
been done once only. Drawing any conclusion from this experiment requires 







Figure 4-4. DNA damage induced by PLK1 inhibition is both telomeric and non-telomeric.  
A549 cells were treated with 10 nM BI2536 or 100 ng/ml nocodazole for 2 hours. Mitotic wash off 
carried out and mitotic cells replated in media containing drug for further 2 hours. Samples were 
collected, cytospun and immuno-stained for γ-H2AX. FISH was performed using a telomere probe (5’-
TTAGGG-3’, green) to detect telomeres. Co-localization of γ-H2AX and FISH shows telomere dysfunction 
induced foci (TIFs). (A) Representative microscopic images are shown. (B) Quantification of TIF versus 






Figure 4-5. Mitotic arrest induced by PLK1 inhibitor results in loss of TRF2.   
U2OS cells were treated with 100 ng/ml Nocodazole or 25 nM BI2536 for 2 hours. Mitotic cells were 
then separated and re-plated in the media containing drugs for further 4 hours. Cells were then 
collected, cytospun and immuno-stained with antibody against TRF2. Number of TRF2 foci was then 
counted in at least 25 mitotic cells. The data shown is for 1 experiment (minimum of 25 cells counted).  
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4.3.5 DNA damage caused by PLK1 inhibition is not caspase dependent 
The DNA damage-induced mitotic arrest by microtubule poisons has been 
reported to be caspase dependent (Colin et al., 2015; Hain et al., 2016; Orth et 
al., 2012). We were therefore interested to see if caspases play any role in the 
DNA damage caused by PLK1 inhibition-induced mitotic arrest. To test this, we 
used 2 different approaches. One approach was to use the pan-caspase 
inhibitor z-VAD-fmk to check the caspase dependency. Another approach was 
to use cells that express a non-cleavable mutant of ICAD (inhibitor of CAD) to 
check the CAD dependency of the damage induced (CAD works downstream of 
caspases and will be explained below).  
Firstly, cell were treated with mitotic poisons, nocodazole and BI2536, in 
presence or absence of z-Vad fmk. Surprisingly we noticed that the DNA 
damage induced by BI2536 is not inhibited by z-VAD-fmk in contrast to the 
nocodazole control (Figure 4-6). These data indicate that inhibition of PLK1 
induces a different, caspase independent DNA damage pathway in mitotically 
arrested cells (as compared with nocodazole).  
To further investigate caspase dependency of the damage and confirm our 
data, involvement of CAD (caspase activated DNase) was investigated by using 
a cell line which expresses YFP-ICAD. ICAD (inhibitor of CAD) acts as the 
endonuclease CAD inhibitor. In response to apoptotic stimuli, caspases cleave 
ICAD, as a result CAD is not inhibited anymore and can cause DNA 
fragmentation and apoptosis (Figure 4-7). The cells that we used were 
expressing a non-cleavable mutant of ICAD (D117E/D224E) that inhibits CAD 
endonuclease independently of caspase activity (kindly provided by team 
members; Dr. Karolina Hain and Dr. Desiree Rutschow). They have been stably 
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transfected with a doxycycline-inducible YFP-ICAD mutant integrated at FRT 
sites in U2OS Flp–In cells. As in these cells ICAD cannot be cleaved by 
caspases, so CAD remains inhibited and we expect to see reduction of DNA 
damage if the damage is CAD dependent.  
As indicated in Figure 4-8, ICAD mutant cells show a significant reduction of γ-
H2AX foci after treatment with nocodazole compared to control (YFP cells). This 
is consistent with previous results in our laboratory (Hain et al., 2016). However, 
we do not see a significant reduction in γ-H2AX foci in BI2536 treated ICAD-
mutant cells. This finding agrees with the lack of effect of caspase inhibitor on γ-
H2AX foci after treatment with BI2536 and suggests that PLK1 inhibition 




  Figure 4-6. DNA damage induced by BI2536 is not caspase dependent.  
(A) U2OS cells were treated with 25 nM BI2536 or 100 ng/ml nocodazole (in presence or absence of 
20 µM zVAD-fmk) for 2 hours. Mitotic wash off was then carried out and mitotic cells were re-plated 
in the same media (containing drugs) for further 4 hours. Cells were then collected and proceeded 
for immuno-fluorescence. (B) A549 cells were treated with 10 nM BI2536 or 100 ng/ml nocodazole 
for 2 hours, in presence or absence of 20 µM zVAD-fmk. Mitotic wash off was then carried out and 
mitotic cells were re-plated in the same media (containing drugs) for further 2 hours. Cells were then 
collected and proceeded for immuno-fluorescence. These results are average of 3 independent 









Figure 4-7. Schematic representation of caspase dependent DNA damage.  
In response to apoptotic stimuli, caspases mediate the cleavage of ICAD, an inhibitor of 





Figure 4-8. DNA damage induced by BI2536 is not CAD dependent.  
(A) Asynchronous stable U2OS YFP and YFP-ICAD mutant cells were collected and treated with or 
without doxycycline. Immuno-blotting was performed to check ICAD expression in ICAD mutant 
cells. (B) Cells were treated with 25 nM BI2536 or 100 ng/ml nocodazole for 2 hours. After mitotic 
wash off, mitotic cells were re-plated in the media containing BI2536 or nocodazole respectively for 
further 4 hours. Cells were then collected, cytospun and immuno-stained with anti-γ-H2AX antibody. 
These results are average of 4 independent experiments (western blotting has been performed 





4.3.6 ATR and DNA-PK are involved in DNA damage response caused by 
PLK1 inhibition  
Several protein kinases are believed to sense DNA damage among which ATM 
(ataxia telangiectasia, mutated), ATR (ATM- and Rad3-related) and DNA 
double-strand break repair enzyme DNA-PK (DNA dependent protein kinase) 
are well known. These kinases belong to the phosphatidylinositol-3-kinase-
related protein kinases (PIKKs) family which phosphorylate H2AX at ser139 (γ-
H2AX) during DNA damage response (Yang et al., 2003). We were interested in 
knowing whether the mitotic DNA damage induced by PLK1 inhibition is under 
the influence of these kinases.  
Chemical inhibitors of ATM, ATR and DNA-PK were used to test whether 
inhibiting these kinases have any effect on the number of γ-H2AX foci formed 
by inhibition of PLK1. Figure 4-9 indicates that following the inhibition of DNA-
PK and ATR, the number of γ-H2AX foci in BI2536 treated cells reduces 
whereas ATM inhibition showed no differences. Nocodazole induced γ-H2AX 
foci on the other hand was found to be influenced by DNA-PK inhibitor only. 
Since the results are marginal, having a control experiment would have been 
helpful to determine the effectiveness of the kinase inhibitors. For example, 
western blot analysis could have been performed for the kinases used, to check 








Figure 4-9. DNA damage response caused by PLK1 inhibition is partly dependent on ATR and DNA-PK. 
A549 cells were treated with 10 nM BI2536 or 100 ng/ml nocodazole with or without 30 minutes pre-
treatment with different DNA damage sensing kinase inhibitors; ATM inhibitor KU55933 (10 µM), ATR 
inhibitor NU6027 (10 µM), DNA-PK inhibitor NU7441 (1 µM).  After 2 hours of incubation, mitotic wash 
off was carried out and mitotic cells were re-plated in the media containing nocodazole/BI2536 for 
further 2 hours. Cells were collected and proceeded for immune-staining. These results are average of 3 




4.3.7 Aurora B kinase activity is important in DNA damage response 
observed by PLK1 inhibition 
Spindle assembly checkpoint is responsible for monitoring the phases of 
mitosis. SAC prevents anaphase onset by targeting the anaphase promoting 
complex/cyclosome (APC/C, an E3 ubiquitin ligase). APC targets cell cycle 
proteins for degradation by 26S proteasome and by that it triggers the transition 
from metaphase to anaphase (Acquaviva and Pines, 2006). Aurora B is a 
kinase involved in SAC signalling. It is involved in error correction of 
microtubule-kinetochore attachment and, as a result, correct chromosome 
segregation (Kelly and Funabiki, 2009).  
It has been reported that telomeric DNA damage induced by microtubule 
poison, Taxol, is dependent on Aurora B (Hayashi et al., 2012). We were 
therefore interested to investigate whether the DNA damage induced by PLK1 
inhibition is dependent on Aurora B kinase activity too. An inhibitor of Aurora B 
(ZM 447439) was used to test if Aurora B is involved in the DNA damage 
caused by prolonged mitosis. Aurora B was found to be partially responsible for 
the DNA damage response observed by both nocodazole and BI2536 as the 
number of γ-H2AX foci reduced in cells pre-treated with Aurora B inhibitor 











Figure 4-10. Aurora kinase B is involved in DNA damage response induced by PLK1 inhibition. 
A549 cells treated with 10 nM BI2536 or 100 ng/ml nocodazole with or without 30 minutes pre-
treatment with Aurora B inhibitor (ZM447439).  After 2 hours of incubation, mitotic wash off was 
performed and mitotic cells were re-plated in the media containing drugs and incubated for further 
2 hours. Cells were then collected and proceeded for immuno-fluorescence. These results show the 





4.3.8 PLK1 inhibition could cause re-activation of DNA repair in mitosis 
Mitotic cells and interphase cells respond differently to DNA damage. In 
interphase cells, DNA damage causes a halt in the cell cycle progression 
followed by recruitment of DNA repair factors to maintain genome integrity. On 
the other hand, in mitotic cells, a primary DNA damage response is activated 
(detection and marking the damage) which does not proceed to cell cycle arrest 
unless the damage is very severe. Also, DNA repair is shut down during mitosis 
and repair is delayed until cells exit mitosis. This reprogramming of DDR 
signalling shows that cells prioritise mitotic progression over activation of full 
DDR (signifying the importance of short mitosis) (Giunta et al., 2010; Heijink et 
al., 2013).  
53BP1 one of the components of DNA damage repair pathway is 
phosphorylated by CDK1 and PLK1 in mitosis. Priming phosphorylation of 
53BP1 by CDK1 generates a docking site for PLK1. PLK1 can then 
phosphorylate 53BP1, as a result modified 53BP1 cannot bind to the chromatin. 
This could be the reason why 53BP1 cannot localise to the site of DNA damage 
during mitosis  (Benada et al., 2015; Orthwein et al., 2014) (Figure 4-11). This 
raised the possibility that inhibition of PLK1, and thus inhibition of 53BP1 
phosphorylation by PLK1, could re-activate DNA repair in mitosis.  
To investigate this, we used the PLK1 inhibitor, BI2536, to treat A549 cells. 
Immuno-fluorescence studies were performed on fixed cells using an antibody 
against 53BP1 and number of 53BP1 foci in mitotic cells were counted. As 
results demonstrate (Figure 4-12 A), BI2536 treated mitotic cells show more 
53BP1 foci as compared with normal mitotic cells and even compared to 
nocodazole treated cells. Surprisingly when stained with both 53BP1 and γ-
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H2AX to check their co-localization, many 53BP1 foci were not co-localized with 
γ-H2AX (Figure 4-12 B).  
Results were further confirmed by using U2OS GFP-53BP1 cells which express 
doxycycline-inducible GFP-53BP1. These cells were generated in our 
laboratory by Dr. Rutschow. Immuno-fluorescence studies were performed on 
fixed cells and number of 53BP1 foci were counted (using GFP signal). Here 
again similar results were obtained; BI2536 treated mitotic cells showed 53BP1 
foci more than normal mitotic cells and even more than nocodazole treated cells 











Figure 4-11. Schematic showing inhibition of 53BP1 recruitment to the site of DNA damage in mitosis. 
53BP1 is phosphorylated by PLK1 and CDK1 in mitosis. CDK1 phosphorylates 53BP1 and generates a 







Figure 4-12. Re-activation of DNA repair in mitosis by inhibition of PLK1.  
(A) A549 cells were treated with nocodazole or BI2536 for 2 hours. Floating cells were then collected 
and incubated for another 2 hours in the same media. Cells were then collected, cytospun and 
immuno-stained with anti-53BP1 and γ-H2AX antibody. (B) Co-localisation of anti-53BP1 and γ-H2AX 
foci in the samples in figure A were measured. (C) U2OS cells expressing GFP-53BP1 were treated 
with 100 ng/ml nocodazole or 25 nM BI2536 and incubated for 2 hours. Floating cells were then 
collected and incubated for another 4 hours in media containing nocodazole/BI2536. Cells were then 
collected, cytospun and proceeded for immune-fluorescence. These results show the average of at 




4.3.9 Cells treated with BI2536 show more surviving colonies as 
compared with nocodazole treated cells 
We were then interested to see the long-term effects of mitotic stress on cell 
survival and proliferation. A549 and U2OS cells were seeded and treated with 
nocodazole or BI2536. Mitotic wash off was carried out after 2 hours and 
collected mitotic cells were re-seeded in the media containing drug and 
incubated for further 2 or 4 hours (A549 or U2OS). Mitotic cells were then 
collected and washed twice to ensure no residual drugs have left. Cells were 
then counted and seeded in dishes containing fresh media. Normal mitotic cells 
were counted and seeded as the control for the experiment. Clonogenic survival 
assays were performed when colonies reached desirable size.  
Analysis of the results showed that the number of surviving colonies is greater 
when cells are treated with BI2536 compared to nocodazole (Figure 4-13). 
These findings are particularly interesting because if we look back at the results 
we obtained in previous experiments shown in Figure 4-6, the number of γ-
H2AX foci in cells treated with BI2536 is higher compared to nocodazole treated 
cells so it was expected to see less number of surviving colonies in BI2536 







Figure 4-13. Cells treated with BI2536 show more surviving colonies compare to nocodazole 
treated cells.  
(A) A549 cells were treated with 100 ng/ml nocodazole or 10 nM BI2536 for 2 hours. Mitotic wash 
off was then carried out and mitotic cells re-plated in the media containing drugs for further 2 hours. 
(B) U2OS cells treated with 100 ng/ml nocodazole or 25 nM BI2536 for 2 hours. Mitotic wash off was 
then carried out and mitotic cells re-plated in the media containing drug for further 4 hours. Cells 
were then counted, and 1500 cells were added to each 10 cm dish containing fresh media. Following 
9-10 days incubation number of survived colonies were counted in each dish. The figure shows 
average of 3 experiments and representative images. These results are average/representative 




4.4    Discussion 
The DNA damage after prolonged mitosis and the underlying mechanisms 
remain interesting areas of research to be investigated. Some mechanisms 
have been proposed for this, such as partial activation of the apoptotic pathway 
which causes partial activation of CAD and limited DNA damage (Orth et al., 
2012) but still more research needs to be done to fully understand it.  
We have shown in this chapter that PLK1 inhibition arrests the cells in mitosis 
and we have tried to use this to widen our understanding of mitotic regulation 
and DNA damage after prolonged mitosis and the consequences of this 
inhibition. As our group and most of the published literature have previously 
worked on the mitotic arrest induced by microtubule poisons, parts of this 
chapter compared how PLK1 inhibition-induced mitotic arrest and the 
consequences associated with such arrest are different from that induced by 
microtubule poisons.  
In agreement with published literature, treatment with a PLK1 inhibitor resulted 
in mitotic arrest and consequent DNA damage in our experiments (Lénárt et al., 
2007; Steegmaier et al., 2007; Driscoll et al., 2014). We also used nocodazole 
and confirmed the mitotic arrest and resulting DNA damage that have been 
reported with microtubule poisons before (Dalton et al. 2007; Hain et al., 2016; 
Orth et al., 2012). However, our studies indicated a different DNA damage 
response mechanism between microtubule poisons and the PLK1 inhibitor.  
Several lines of evidence have shown the initiation of a DNA damage response 
following prolonged mitosis by microtubule poisons; however the damage had 
been reported to be mainly on telomeres and was suggested to be caspase 
dependent (Hain et al., 2016, Orth et al., 2012, Hayashi et al., 2012) . Findings 
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of this chapter suggest that the PLK1 inhibition causes formation of γ-H2AX foci 
equally at the telomeric and non-telomeric regions. Also, we found that the DNA 
damage induced by PLK1 inhibition is not caspase or CAD dependent as using 
a pan caspase inhibitor did not significantly reduced the number of γ-H2AX foci, 
neither did the use of ICAD mutant cells.  
TRF2 loss was investigated and it seems to be greater following nocodazole 
treatment compared to BI2536 treatment. This observation could be true since 
nocodazole results mainly in telomeric foci, whereas the ratio of telomeric and 
non-telomeric foci in BI2536 treated cells are equal. However, drawing any 
conclusions from this experiment requires further experimentations as the 
experiment has not been done in replicates due to shortage of time. Also, it 
would have been helpful to count the γ-H2AX and TRF2 foci in the same 
experiment in order to eliminate the possibility that the higher loss of TRF2 
observed by nocodazole is due to higher DNA damage.   
In nocodazole-induced mitotic arrest, DNA-PK was found to be the main kinase 
involved in the mitotic DNA damage response, which is consistent with previous 
report (Hain et al., 2016). However, in mitotic arrest caused by PLK1 inhibition, 
we found that both ATR and DNA-PK are involved. Combining DNA damage 
sensing kinase inhibitors together would be a helpful approach to determine the 
significance of these kinases in the DNA damage response observed and 
investigate if there might be redundant pathways involved.  
Another interesting concept investigated in this chapter, is the fact that using a 
PLK1 inhibitor results in formation of 53BP1 foci, indicating that PLK1 inhibition 
might activate DNA-repair in mitosis. Interestingly, 53BP1 foci are not all 
localised at γ-H2AX foci. What would be the consequences of recruitment of 
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53BP1 and activation of DNA repair in mitosis? It would be an interesting area 
of research to be followed. Clonogenic assays indicate that BI2536 treated cells 
form more colonies compared to nocodazole treated ones. This is particularly 
interesting because when looking at the number of γ-H2AX foci, the numbers 
are higher with PLK1 inhibitor compared to nocodazole. Could it be related to 
reactivation of DNA repair in mitosis by PLK1 inhibitor? Or does it mean that 
PLK1 inhibited cells undergo repair more than nocodazole treated cells? This 
remains to be investigated. More clonogenic assay investigations for cells 
treated with PLK1 inhibitor with pre-treatment with kinase inhibitors could give 
us an indication of the effect of combination of these agents on survival of 
cancer cells in long term.  
Overall, the data in this chapter add on the previously published literature about 
mitotic arrest-induced DNA damage response and demonstrate some 
differences in the DNA damage response mechanisms observed by PLK1 
inhibitor and nocodazole. The exact cause of the damage is unknown. Further 
work could attempt to address this question and also what would be the 









Given the importance of PLK1 in oncogenesis and its many roles in cell cycle, 
especially during mitosis, research into regulation of this protein is an important 
area for investigations. In this thesis, we have tried to address two of the key 
questions in PLK1 research and what we have concluded is discussed below.  
Investigating PLK1 as a target of p53 transcriptional regulation, was one of 
the issues that tried to be addressed in this thesis. The main focus was in light 
of the recent model (p53-p21-DREAM-CDE/CHR) proposed by Fischer, Quaas, 
Nickel, et al. (2015). While trying to reproduce the data that show p53 represses 
PLK1, different p53-inducing agents seemed to give rise to completely different 
changes in the PLK1 levels. Nutlin, a pharmacological inhibitor of MDM2, 
caused significant depletion of PLK1, whereas an agent like etoposide appear 
to stimulate PLK1 levels. Cell cycle analysis revealed that different drugs lead to 
different cell cycle profile and therefore we concluded that the apparent 
regulation of PLK1 by p53 might be a reflection of cell cycle periodicity. 
Whether p53 represses PLK1 through direct or indirect mechanisms and exactly 
which elements/molecules are involved, remained unresolved. The data in this 
thesis support a cell line dependency for the mechanism(s) by which this 
phenomenon occurs. The conflicting data published by different groups could 
indicate the possibility of multiple mechanisms. Consistent with that hypothesis, 
our findings showed that in U2OS cells CDE/CHR elements are only partly 
responsible for PLK1 repression and there should be other mechanism(s) 
involved. Figure 5-1 depicts our proposed model on potential mechanisms p53 










Figure 5-1. Schematic representation of possible p53 mediated PLK1 repression mechanisms.  
Various proposed p53 mediated mechanisms for PLK1 repression, has been depicted. P53 can repress 
PLK1 by direct interaction with the promoter at p53REs. p53 has also been reported to form an 
inhibitory p53-E2F1-DNA complex and inhibit E2F1 mediated expression of PLK1. p53 has been 
suggested to mediate PLK1 repression through its downstream target p21 with several different 
mechanisms. One mechanism involves p21 mediated inhibition of cyclin/CDK, this keeps p130/p107 in 
hypo phosphorylated state and hence stabilisation of DREAM complex. Binding of DREAM complex to 
CDE/CHR mediates PLK1 repression. p53 induced p21 can also replace CDK2 in interacting with NF-YA 
and cause CCAAT box to have repressive function. p53 can also inhibit FOX M1, which acts in a positive 
feedback loop with PLK1. Could DREAM complex associate with the E2F binding sites in the PLK1 





What would be the consequences of p53 mediated repression of PLK1 in long 
term and how it can affect the cell fate? Further work could attempt to address 
this key question. PLK1 is a central protein during mitosis and many mitotic 
events depend on PLK1 activity. If p53 mediated repression of PLK1 (as a 
result of treatment with Nutlin or DNA damaging agents) arrests the cells and/or 
prevents them from entry into mitosis, it would be interesting to know what will 
happen in long term? Would PLK1 repression recover and would cells continue 
to cycle? Or long-term arrest triggers the apoptotic signals?  
Since p53 not only represses PLK1, but many other G2/M cell cycle genes in 
response to DNA damage, understanding the mechanism(s) of repression of 
PLK1 by p53 could potentially apply to other genes involved in G2/M DNA 
damage checkpoint. In fact, it would be interesting to see if the same 
mechanism(s) can apply to other G2/M expressing genes that are p53 targets. 
p53-mediated regulation of G2/M genes is important as it causes G2/M arrest in 
response to DNA damage. This arrest provides time for repair of the damage or 
an opportunity to permanently arrest severely damaged cells, both of which are 
important to protect organisms against accumulation of aberrant cells (Taylor 
and Stark, 2001).  
Since PLK1 also inhibits the function of p53 (as discussed in section 1.2.7), 
PLK1 downregulation is important not only because it halts the cell cycle 
progression but for maintaining p53 activity and functions during stress 
conditions. Downregulation of PLK1 could mean that p53 can recruit to the 
target genes without disruption by PLK1. 
As PLK1 has a central role during different events of mitosis, and because it is 
required for the progression of the cell cycle, further investigations of how this 
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protein is regulated could potentially lead to better combination therapies or 
could eventually lead to developing new therapies.  
Trying to develop novel therapies that target specific proteins with differential 
expression in normal and cancer cells is one of the important approaches in 
cancer therapy. PLK1 is one such protein and hence a potential target in cancer 
treatment. Therefore, part of this thesis investigated the mitotic arrest and 
resultant DNA damage response induced by PLK1 inhibition. Consistent 
with other studies (Lénárt et al., 2007; Steegmaier et al., 2007; Driscoll et al., 
2014), our results showed that inhibiting PLK1 results in mitotic arrest and 
formation of γ-H2AX foci, an indicator of DNA damage. However, in addition to 
this, the data in this thesis showed that the resulting damage occur equally at 
both telomeric and non-telomeric regions and was found to be independent of 
caspases. These data are different from the mitotic arrest induced DNA damage 
resulting from treatment with microtubule poisons which was reported to be 
mostly telomeric and caspase dependent (Hain et al., 2016; Orth et al., 2012; 
Hayashi et al., 2012). The caspase-independency of the DNA damage induced 
by PLK1 inhibition has been recently reported using a different approach (Smith 
et al., 2017). Thus, the data in this thesis add to the previous published 
literature by demonstrating some differences in the mitotic arrest-induced DNA 
damage response observed by PLK1 inhibition and microtubule poisons.  
One of the very interesting concepts investigated in this thesis, is the fact that 
PLK1 inhibitor re-recruits DNA repair factor 53BP1 in mitosis. Why 53BP1 foci 
are not all localised at γ-H2AX foci is unclear. Anyhow, the recruitment of DNA 
repair factors by PLK1 inhibition in mitosis is not beneficial. Firstly, because 
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DNA repair activation in mitosis prolongs the period of stressful mitosis which 
could be catastrophic and potentially lead to acquiring even more damage. 
Also, repair requires disruption of the highly compacted chromosome structure, 
probably causing various segregation defects (Giunta and Jackson, 2011). 
Additionally, homologous recombination (HR) does not happen during mitosis 
due to condensed chromatin. The only error correction machinery which may 
occur in mitosis is non-homologous end joining (NHEJ) which is not error free. 
Thus, DNA repair activation in mitosis by NHEJ can cause translocation of 
chromosomes and telomere fusion which is very harmful and can cause 
aneuploidy (Benada et al., 2015). This finding highlights the importance of 
further investigating the chromosomal abnormalities in cells that have 
undergone treatment with PLK1 inhibitor. This finding also suggests 









Figure 5-2. Schematic representation of events occurring after PLK1 inhibition in mitosis.  
PLK1 inhibition results in prolonged mitosis and resultant DNA damage response. This DNA damage was 
found to be both telomeric and non-telomeric and was attenuated by inhibition of ATR/DNA-PK/Aurora 
B. PLK1 inhibition causes recruitment of 53BP1 to the site of damage and may activate DNA repair in 




In this thesis we have performed experiments to investigate the level of DNA 
damage in mitotically arrested cells. We still don’t know what the consequences 
of PLk1 inhibition would be when cells exit mitosis either by releasing them from 
drug contained media or if they manage to escape/slip from mitosis. 
Investigating these would be beneficial as it could give us information about 
how PLK1 inhibition affects cell fate.  
Understanding the mechanisms PLK1 inhibitors follow and the cross talk 
between PLK1 and other proteins could guide clinicians when choosing PLK1 
inhibitors for patients with specific tumour genotypes. For example, many 
studies have shown that p53 status of the cancer cells could determine the level 
of effectiveness of PLK1 inhibitors, with p53 being a disadvantage in PLK1 
inhibition therapy (Smith et al., 2017; McKenzie et al., 2010; Degenhardt et al., 
2010). On the other hand, previous investigations reported that the sensitivity of 
different cancer cells to Taxol are p53 independent (Debernardis et al., 1997; 
Reinecke et al., 2005). Also, in p53 depleted U2OS cells, after mitotic arrest 
with nocodazole, there has been no accumulation of cells in G1 but more 
apoptosis compared to normal U2OS cells (Colin et al. 2015). Since both 
microtubule poisons and PLK1 inhibitors cause arrest in mitosis, it is interesting 
that the presence of p53 is advantageous/ineffective in one therapy and 
adverse in another. 
In our studies we used cell lines with wild type p53. As it has been shown that 
p53 is a disadvantage for therapy when treating the cells with PLK1 inhibitor, 
further investigations would be helpful to determine the differences in the action 
of microtubule poisons and PLK1 inhibitors in p53 null cells. For example, with 
PLK1 inhibitors we observed more damage, but less surviving colonies 
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compared to nocodazole, it would be interesting to see if we get the same 
results in cells with p53 null background.  
The cause of the DNA damage-induced PLK1 inhibition remains to be 
investigated. It is unclear if the DNA damage observed is directly due to mitotic 
arrest or due to the activation of SAC. Understanding these could help in 
developing new strategies for cancer treatment. If the DNA damage trigger is 
mitotic arrest, then prolonging the arrest by means other than SAC activation 
(for example knockdown of activator of APC/C, CDC20) would be beneficial. 
Whereas if trigger is SAC activity, trying to hyper activate SAC (for example by 
partial inhibition of kinetochore protein) could result in improved therapeutic 
mechanisms. 
It will be interesting to characterise the pathway PLK1 inhibition follows in 
mitotic cells in the context of PLK1 as a potential drug target. Understanding 
these mechanisms can help to improve existing therapies and potentially can 
help in developing new agents to treat cancer. Also knowing these mechanisms 
is useful when considering combination therapies. 
Finally, from understanding the biology of PLK1 to its clinical application, there 
is probably a long way to go. Many fundamental questions are still waiting to be 
answered such as: the true relationship between PLK1 and p53 (Liu et al., 
2017), whether PLK1 overexpression in cancers is a cause or consequence of 
cancer (Cholewa et al., 2013)? The key interactive network of PLK1 underlying 
the carcinogenesis (Liu, Sun and Wang, 2017) and how exactly PLK1 inhibition 
can help in cancer therapy. Research into understanding PLK1 itself and its 
regulators/inhibitors, would be advantageous not only in cancer but also in 
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understanding the pathogenesis of other diseases that involve PLK1 
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